test diabète - antidiabetic drugs - type 2 daibetes (NIDD) clinical trials results meta-analysis

<h1> <a href="TM72-54-antidiabetic drugs-test diabète"> <strong>test diabète</strong> - antidiabetic drugs </a> - type 2 daibetes (NIDD) trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> PROactive, 2005 </a> <br> NCT00174993 </td> <td> pioglitazone titrated from 15 mg to 45 mg<br>  <i>versus</i> <br> placebo </td> <td> Inadequately controlled patients with type 2 diabetes who had evidence of macrovascular disease </td> <td> follow-up 34.5 mo<br> n=2605/2633<br> Parallel groups<br> double blind <br> 19 European countries </td> </tr> <tr> <td> <a href="index.html"> Wang, 2005 </a> <br> </td> <td> rosiglitazone 4 mg/d<br>  <i>versus</i> <br> control </td> <td> patients with diabetes and CAD who had undergone percutaneous coronary intervention </td> <td> follow-up 6 months<br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> PERISCOPE, 2008 </a> <br> NCT00225277 </td> <td> pioglitazone 15 to 45 mg<br>  <i>versus</i> <br> glimepiride, 1 to 4 mg </td> <td> patients with coronary disease and type 2 diabetes </td> <td> follow-up 18 months<br> n=274/273<br> Parallel groups<br> double blind <br> North and South America </td> </tr> <tr> <td> <a href="index.html"> PNFP-010, </a> <br> </td> <td> Pioglitazone + sulfonylurea<br>  <i>versus</i> <br> Sulfonylurea </td> <td> patients with type 2 diabetes </td> <td> follow-up 16 wk<br> n=373/187<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> PNFP-014, </a> <br> </td> <td> Pioglitazone insulin<br>  <i>versus</i> <br> Placebo + insulin </td> <td> patients with type 2 diabetes </td> <td> follow-up 16 wk<br> n=379/187<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> PNFP-027, </a> <br> </td> <td> Pioglitazone + metforminrea<br>  <i>versus</i> <br> Placebo +metformin </td> <td> patients with type 2 diabetes </td> <td> follow-up 16 wk<br> n=168/160<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> PNFP-026, </a> <br> </td> <td> Pioglitazone<br>  <i>versus</i> <br> Placebo </td> <td> patients with type 2 diabetes </td> <td> follow-up 16 wk<br> n=101/96<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> OPI-502, </a> <br> </td> <td> Pioglitazone + insulin<br>  <i>versus</i> <br> Placebo + insulin </td> <td> Insulin-dependent DM-2 </td> <td> follow-up 20 wk<br> n=110/112<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> PNFP-012, </a> <br> </td> <td> Pioglitazone<br>  <i>versus</i> <br> Placebo </td> <td> patients with type 2 diabetes </td> <td> follow-up 24 wk<br> n=176/84<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> OPI-504, </a> <br> NCT00521820 </td> <td> Pioglitazone<br>  <i>versus</i> <br> Sulfonylurea </td> <td> patients with type 2 diabetes andmild to moderate congestive heart failure </td> <td> follow-up 24 wk<br> n=262/256<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> GLAI, </a> <br> NCT00331487 </td> <td> Pioglitazone<br>  <i>versus</i> <br> Rosiglitazone </td> <td> patients with type 2 diabetes and dyslipidemia </td> <td> follow-up 24 wk<br> n=369/366<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> PNFP-001, </a> <br> </td> <td> Pioglitazone<br>  <i>versus</i> <br> Placebo </td> <td> patients with type 2 diabetes </td> <td> follow-up 26 wk<br> n=329/79<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> EC405, </a> <br> </td> <td> Pioglitazone<br>  <i>versus</i> <br> Sulfonylurea </td> <td> patients with type 2 diabetes </td> <td> follow-up 52 wk<br> n=624/626<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> OPI-501, </a> <br> </td> <td> Pioglitazone<br>  <i>versus</i> <br> Sulfonylurea </td> <td> Recently diagnosed DM-2 </td> <td> follow-up 56 wk<br> n=251/251<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> EC404, </a> <br> </td> <td> Pioglitazone<br>  <i>versus</i> <br> Metformin </td> <td> patients with type 2 diabetes </td> <td> follow-up 52 wk<br> n=597/597<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> EC409, </a> <br> </td> <td> Pioglitazone + sulfonylurea<br>  <i>versus</i> <br> Metformin + sulfonylurea </td> <td> patients with type 2 diabetes </td> <td> follow-up 104 wk<br> n=319/320<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> EC410, </a> <br> </td> <td> Pioglitazone + metformin<br>  <i>versus</i> <br> Sulfonylurea + metformin </td> <td> patients with type 2 diabetes </td> <td> follow-up 104 wk<br> n=317/313<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> OPI-520, </a> <br> NCT00521742 </td> <td> Pioglitazone<br>  <i>versus</i> <br> Sulfonylurea </td> <td> Inadequately controlled DM-2 with mild cardiac disease(New York HeartAssociation Class I) </td> <td> follow-up 52 wk<br> n=151/149<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> OPI-506, 0 </a> <br> NCT00494312 </td> <td> Pioglitazone<br>  <i>versus</i> <br> Sulfonylurea </td> <td> Inadequately controlled DM-2 </td> <td> follow-up 156 wk<br> n=1051/1046<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/011 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Placebo </td> <td> patients with type 2 diabetes </td> <td> follow-up 24 wk<br> n=357/176<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/020 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Glyburide </td> <td> patients with type 2 diabetes </td> <td> follow-up 52 wk<br> n=391/207<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/093 , </a> <br> </td> <td> Rosiglitazone with or without metformin<br>  <i>versus</i> <br> Metformin </td> <td> patients with type 2 diabetes poorly controlled on Met </td> <td> follow-up 26 wk<br> n=213/109<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/094 , </a> <br> </td> <td> Rosiglitazone and metformin<br>  <i>versus</i> <br> Metformin </td> <td> Type 2 DM poorly controlled on Met </td> <td> follow-up 26 wk<br> n=232/116<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 100684 , </a> <br> NCT01045590 </td> <td> Rosiglitazone and glyburide<br>  <i>versus</i> <br> Glyburide </td> <td> Korean patients with type 2 DM </td> <td> follow-up 52 wk<br> n=43/47<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/143 , </a> <br> NCT00333723 </td> <td> Rosiglitazone and glyburide<br>  <i>versus</i> <br> Glyburide </td> <td> Type 2 DM poorly controlled on glyburide </td> <td> follow-up 24 wk<br> n=121/124<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/211 , </a> <br> </td> <td> Rosiglitazone and usual care<br>  <i>versus</i> <br> Usual care </td> <td> Type 2 DM with CHF </td> <td> follow-up 52 wk<br> n=110/114<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/284 , </a> <br> NCT00501020 </td> <td> Rosiglitazone and metformin<br>  <i>versus</i> <br> Metformin </td> <td> patients with type 2 diabetes </td> <td> follow-up 24 wk<br> n=382/384<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 712753/008 , </a> <br> NCT00241605 </td> <td> Rosiglitazone and metformin<br>  <i>versus</i> <br> Metformin </td> <td> Type 2 DM poorly controlled on Met </td> <td> follow-up 48 wk<br> n=284/135<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> AVM100264 , </a> <br> NCT00359112 </td> <td> Rosiglitazone and metformin<br>  <i>versus</i> <br> Metformin and sulfonylurea </td> <td> Overweight patients with type 2 DM poorly controlled on Met </td> <td> follow-up 52 wk<br> n=294/302<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> BRL 49653C/185 , </a> <br> </td> <td> Rosiglitazone with or without metformin<br>  <i>versus</i> <br> Usual care with or without metformin </td> <td> patients with type 2 diabetes </td> <td> follow-up 32 wk<br> n=563/142<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> BRL 49653/334 , </a> <br> NCT00306644 </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Placebo </td> <td> patients with type 2 diabetes or insulin resistance syndrome </td> <td> follow-up 52 wk<br> n=278/279<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> BRL 49653/347 , </a> <br> NCT00054782 </td> <td> Rosiglitazone and insulin<br>  <i>versus</i> <br> Insulin </td> <td> patients with type 2 diabetes poorly controlled on insulin </td> <td> follow-up 24 wk<br> n=418/212<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/015 , </a> <br> </td> <td> Rosiglitazone and sulfonylurea<br>  <i>versus</i> <br> Sulfonylurea </td> <td> patients with type 2 diabetes </td> <td> follow-up 24 wk<br> n=395/198<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/079 , </a> <br> </td> <td> Rosiglitazone with or without glyburide<br>  <i>versus</i> <br> Glyburide </td> <td> patients with type 2 diabetes poorly controlled on maximum dose of Gly </td> <td> follow-up 26 wk<br> n=203/106<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/080 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Glyburide </td> <td> patients with type 2 diabetes </td> <td> follow-up 156 wk<br> n=104/99<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/085 , </a> <br> </td> <td> Rosiglitazone and insulin<br>  <i>versus</i> <br> Insulin </td> <td> patients with type 2 diabetes </td> <td> follow-up 26 wk<br> n=138/139<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/095 , </a> <br> </td> <td> Rosiglitazone and insulin<br>  <i>versus</i> <br> Insulin </td> <td> patients with type 2 diabetes poorly controlled on insulin </td> <td> follow-up 26 wk<br> n=196/96<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/097 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Glyburide </td> <td> patients with type 2 diabetesDM </td> <td> follow-up 156 wk<br> n=122/120<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/125 , </a> <br> NCT00422955 </td> <td> Rosiglitazone and sulfonylurea<br>  <i>versus</i> <br> Sulfonylurea </td> <td> patients with type 2 diabetes </td> <td> follow-up 26 wk<br> n=175/173<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/127 , </a> <br> </td> <td> Rosiglitazone and glyburide<br>  <i>versus</i> <br> Glyburide </td> <td> patients with type 2 diabetespoorly controlled on Gly </td> <td> follow-up 26 wk<br> n=56/58<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/128 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Placebo </td> <td> patients with type 2 diabetes on concurrent Su </td> <td> follow-up 28 wk<br> n=39/38<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/134 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Placebo </td> <td> patients with type 2 diabetes on Gly and Met </td> <td> follow-up 28 wk<br> n=561/276<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/135 , </a> <br> </td> <td> Rosiglitazone and glipizide<br>  <i>versus</i> <br> Glipizide </td> <td> Elderly patients with type 2 DM </td> <td> follow-up 104 wk<br> n=116/111<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/136 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Placebo </td> <td> patients with type 2 diabetes and chronic renal failure on Su, insulin, or both </td> <td> follow-up 26 wk<br> n=148/143<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/145 , </a> <br> </td> <td> Rosiglitazone and gliclazide<br>  <i>versus</i> <br> Gliclazide </td> <td> patients with type 2 diabetes </td> <td> follow-up 26 wk<br> n=231/242<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/147 , </a> <br> </td> <td> Rosiglitazone and sufonylurea<br>  <i>versus</i> <br> Sulfonylurea </td> <td> Indo-Asian patients with type 2 diabetes </td> <td> follow-up 26 wk<br> n=89/88<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/162 , </a> <br> </td> <td> Rosiglitazone and glyburide<br>  <i>versus</i> <br> Glyburide </td> <td> patients with type 2 diabetes </td> <td> follow-up 26 wk<br> n=168/172<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/234 , </a> <br> </td> <td> Rosiglitazone and glimepiride<br>  <i>versus</i> <br> Glimepiride </td> <td> patients with type 2 diabetes </td> <td> follow-up 26 wk<br> n=116/61<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/330 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Placebo </td> <td> Chronic psoriasis </td> <td> follow-up 52 wk<br> n=1/382<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/331 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Placebo </td> <td> Chronic psoriasis </td> <td> follow-up 52 wk<br> n=706/325<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/137 , </a> <br> NCT00500955 </td> <td> Rosiglitazone and metformin<br>  <i>versus</i> <br> Glyburide and metformin </td> <td> patients with type 2 diabetes </td> <td> follow-up 32 wk<br> n=204/185<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> SB-712753/002 , </a> <br> </td> <td> Rosiglitazone and metformin<br>  <i>versus</i> <br> Metformin </td> <td> patients with type 2 diabetes poorly controlled </td> <td> follow-up 24 wk<br> n=288/280<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> SB-712753/003 , </a> <br> </td> <td> Rosiglitazone and metformin<br>  <i>versus</i> <br> Metformin </td> <td> Mild type 2 DM </td> <td> follow-up 32 wk<br> n=254/272<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> SB-712753/007 , </a> <br> </td> <td> Rosiglitazone with or without metformin<br>  <i>versus</i> <br> Metformin </td> <td> patients with type 2 diabetes without previous drug therapy </td> <td> follow-up 32 wk<br> n=314/154<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> SB-712753/009 , </a> <br> </td> <td> Rosiglitazone, metformin, and insulin<br>  <i>versus</i> <br> Insulin </td> <td> patients with type 2 diabetes with insulin </td> <td> follow-up 24 wk<br> n=162/160<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> 49653/132 , </a> <br> </td> <td> Rosiglitazone and sulfonylurea<br>  <i>versus</i> <br> Sulfonylurea </td> <td> Patients in China with type 2 DM </td> <td> follow-up 24 wk<br> n=442/112<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> AVA100193 , </a> <br> </td> <td> Rosiglitazone<br>  <i>versus</i> <br> Placebo </td> <td> Mild-to-moderate Alzheimer’s disease </td> <td> follow-up 24 wk<br> n=394/124<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> ADOPT, 2006 </a> <br> NCT00279045 </td> <td> Rosiglitazone 4mg twice daily<br>  <i>versus</i> <br> Metformin 1000mg twice daily or glyburide 7.5mg twice daily </td> <td> Recently diagnosed type type 2 diabetes </td> <td> follow-up 4y (median)<br> n=1456/2895<br> Parallel groups<br> double blind <br> United States, Canada, Europe </td> </tr> <tr> <td> <a href="index.html"> RECORD, 2009 </a> <br> NCT00379769 </td> <td> addition of rosiglitazone (4-8 mg daily titrated) to metformin or sulfonylurea, target HbA1c<=7·0%<br>  <i>versus</i> <br> combination of metformin and sulfonylurea, target HbA1c<=7·0% </td> <td> patients with type 2 diabetes onmonotherapy with either metformin or sulfonylurea andin less than optimal blood glucose control (HbA1c >7·0–9·0%) </td> <td> follow-up 5.5 y<br> n=2220/2227<br> Parallel groups<br> open <br> Europe, Australia </td> </tr> <tr> <td> <a href="index.html"> UKPDS (vs SU or INS), 0 </a> <br> </td> <td> Metformin<br>  <i>versus</i> <br> Chlorpropamide, glybenclamide, or insulin </td> <td> Type 2 diabetic patients </td> <td> follow-up 10.7y<br> n=342/951<br> Parallel groups<br> open <br> UK </td> </tr> <tr> <td> <a href="index.html"> UKPDS (v Conven), 0 </a> <br> </td> <td> Metformine<br>  <i>versus</i> <br> diet </td> <td> </td> <td> follow-up 10.7y<br> n=342/411<br> Parallel groups<br> open <br> UK </td> </tr> <tr> <td> <a href="index.html"> DeFronzo (vs glyburide), 1995 </a> <br> </td> <td> Metformin: 500-2500 mg/d<br>  <i>versus</i> <br> glyburide 5-20 mg/d </td> <td> NIDDM </td> <td> follow-up 29 weeks<br> n=210/209<br> Parallel groups<br> double blind <br> US </td> </tr> <tr> <td> <a href="index.html"> Horton (vs PBO), 2000 </a> <br> </td> <td> Metformin: 500 mg/8 h<br>  <i>versus</i> <br> placebo </td> <td> Type 2 diabetes mellitus </td> <td> follow-up 24 weeks<br> n=178/172<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Hallsten (vs PBO), 2002 </a> <br> </td> <td> Metformin: 1 g bid<br>  <i>versus</i> <br> placebo </td> <td> Type II diabetic patients </td> <td> follow-up 26 weeks<br> n=13/14<br> Parallel groups<br> double blind <br> Finland </td> </tr> <tr> <td> <a href="index.html"> Teupe, 1991 </a> <br> </td> <td> Metfformin up to 1700 mg/day (plus diet)<br>  <i>versus</i> <br> control </td> <td> Type 2 diabetic patients </td> <td> follow-up 2 y<br> n=50/50<br> Parallel groups<br> open <br> Canada </td> </tr> <tr> <td> <a href="index.html"> DeFronzo (vs PBO), 1995 </a> <br> </td> <td> Metformin: 850-2550 mg/d<br>  <i>versus</i> <br> placebo </td> <td> NIDDM </td> <td> follow-up 29 weeks<br> n=143/146<br> Parallel groups<br> double blind <br> US </td> </tr> <tr> <td> <a href="index.html"> Horton (vs Nateglinide), 2000 </a> <br> </td> <td> Metformin: 500 mg/8 h<br>  <i>versus</i> <br> Nateglinide: 120 mg/8h </td> <td> Type 2 diabetes mellitus </td> <td> follow-up 24 weeks<br> n=178/179<br> Parallel groups<br> double blind <br> US </td> </tr> <tr> <td> <a href="index.html"> UKPDS (vs insulin), 0 </a> <br> </td> <td> Metformin<br>  <i>versus</i> <br> insulin </td> <td> </td> <td> follow-up 10.7y<br> n=342/409<br> Parallel groups<br> open <br> UK </td> </tr> <tr> <td> <a href="index.html"> UKPDS (vs chlorpropamide), 0 </a> <br> </td> <td> Metformin<br>  <i>versus</i> <br> Chlorpropamide </td> <td> </td> <td> follow-up <br> n=342/265<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> UKPDS (vs glibenclamide), 0 </a> <br> </td> <td> Metformin<br>  <i>versus</i> <br> glybenclamide </td> <td> </td> <td> follow-up 10.7y<br> n=342/277<br> Parallel groups<br> open <br> UK </td> </tr> <tr> <td> <a href="index.html"> APPROACH, 2008 </a> <br> NCT00116831 </td> <td> rosiglitazone at up to 8 mg/day<br>  <i>versus</i> <br> glipizide at 15 mg/day </td> <td> patients with type 2 diabetes and coronary artery disease </td> <td> follow-up 18 months<br> n=333/339<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> HOME, 2009 </a> <br> </td> <td> metformin 850 mg 1-3 times daily<br>  <i>versus</i> <br> placebo </td> <td> Patients with type 2 diabetes </td> <td> follow-up 4.3y<br> n=196/194<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Aschner, 2006 </a> <br> </td> <td> sitagliptin 100 or 200 mg dailym<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Goldstein, 2007 </a> <br> </td> <td> sitagliptin 100 mg daily<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hanefeld, 2007 </a> <br> </td> <td> sitagliptin 25 mg or 50 mg or 100 mg dailyi<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Nonaka, 2008 </a> <br> </td> <td> sitagliptin 100 mg daily<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Raz, 2006 </a> <br> </td> <td> sitagliptin 100 mg or 200 mg daily, imag<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Scott* (sit vs pbo), 2007 </a> <br> </td> <td> sitagliptin 10 mg or 25 mg or 50 mg or 100 mg dailye/pj<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Goldstein (sit vs met), 2007 </a> <br> </td> <td> sitagliptin 100 dailyily<br>  <i>versus</i> <br> metformin 1000 mg or 2000 mg daily;imag </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Scott* (sit vs glipi), 2007 </a> <br> </td> <td> sitagliptin 100 mg daily<br>  <i>versus</i> <br> glipizide 5mg to 20 mg dailyitm </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Charbonnel, 2006 </a> <br> </td> <td> sitagliptin 100 mg daily (add-on to metformin therapy)j<br>  <i>versus</i> <br> placebo (add-on tometformin therapy); </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Goldstein (sit+met vs met), 2007 </a> <br> </td> <td> sitagliptin 50 mg daily plus metformin 1000 or 2000 mg dailyç$4<br>  <i>versus</i> <br> metformin 1000 or 2000 mg daily </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hermansen, 2007 </a> <br> </td> <td> sitagliptin 100 mg daily (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin)ocumen<br>  <i>versus</i> <br> placebo (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin); </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Nauck, 2007 </a> <br> </td> <td> sitagliptin 100 mg daily (add-on to metformin therapy)j<br>  <i>versus</i> <br> placebo (add-on to metformin therapy); </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rosenstock (sit on top pio vs pbo), 2006 </a> <br> </td> <td> sitagliptin 100 mg daily (add-on to pioglitazone therapy)sl˜ðõØ<br>  <i>versus</i> <br> placebo (add-on to pioglitazone therapy); </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Scott** (sit vs pbo on top met), 2007 </a> <br> </td> <td> sitagliptin 100 mg daily (add-on to metformin therapy)j<br>  <i>versus</i> <br> placebo (add-on to metformin therapy). </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Dejager, 2007 </a> <br> </td> <td> vildagliptin 50 mg or 100 mg daily, imag<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Mimori, 2006 </a> <br> </td> <td> vildagliptin 20 mg or 50 mg or 100 mg daily<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Pi-Sunyer, 2007 </a> <br> </td> <td> vildagliptin 50 mg or 100 mg daily, imag<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Pratley, 2006 </a> <br> </td> <td> vildagliptin 50 mg daily<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Ristic, 2005 </a> <br> </td> <td> vildagliptin 25mg or 50mg or 100mg daily<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Scherbaum, 2008 </a> <br> </td> <td> vildagliptin 50 mg daily<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rosenstock* (vilda vs rosi), 2007 </a> <br> </td> <td> vildagliptin 100 mg daily dailym<br>  <i>versus</i> <br> rosiglitazone 8 mg dailyailyitm </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rosenstock** (vilda vs pio), 2007 </a> <br> </td> <td> vildagliptin 100 mg daily dailym<br>  <i>versus</i> <br> pioglitazone 30 mg dailyailyitm </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Schweizer, 2007 </a> <br> </td> <td> vildagliptin 100mg<br>  <i>versus</i> <br> metformin up to 2000 mg dailyimag </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Ahren, 2004 </a> <br> </td> <td> vildagliptin 50 mg daily (add-on to metformin therapy)j<br>  <i>versus</i> <br> placebo (add-on to metformin therapy)mag </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Bolli, 2008 </a> <br> </td> <td> vildagliptin 100 mg daily (add-on to metformin therapy)<br>  <i>versus</i> <br> pioglitazone 30 mg daily (add-on to metformin therapy)j </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Bosi, 2007 </a> <br> </td> <td> vildagliptin 50 or 100 mg daily (add-on to metformin therapy)m<br>  <i>versus</i> <br> placebo (add-on to metformin therapy)mag </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Fonseca, 2007 </a> <br> </td> <td> vildagliptin 100 mg daily (add-on to insulin therapy)y)<br>  <i>versus</i> <br> placebo (add-on to insulin therapy)y)mag </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Garber, 2007 </a> <br> </td> <td> vildagliptin 50 or 100 mg daily (add-on to pioglitazone therapy)<br>  <i>versus</i> <br> placebo (add-on to pioglitazone therapy) </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rosenstock** (vilda + pio vs pio), 2007 </a> <br> </td> <td> vildagliptin 50 mg or 100 mg daily plus 15 mg or 30 mg pioglitazone dailyi<br>  <i>versus</i> <br> pioglitazone 30 mg daily </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Madsbad (vs Glimepiride), 2004 </a> <br> </td> <td> Liraglutide 0.045–0.75 mg daily<br>  <i>versus</i> <br> Glimepiride </td> <td> </td> <td> follow-up 12 weeks<br> n=135/26<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Vilsboll, 2008 </a> <br> </td> <td> Liraglutide 0.65–1.90 mg daily<br>  <i>versus</i> <br> Placebo </td> <td> patients with Type 2 diabetes </td> <td> follow-up 14 weeks<br> n=123/40<br> parallel groups<br> double blind (not adequate) <br> </td> </tr> <tr> <td> <a href="index.html"> Seino, 2008 </a> <br> NCT00154414 </td> <td> Liraglutide 0.1–0.9 mg daily <br>  <i>versus</i> <br> Placebo </td> <td> Japanese subjects with type 2 diabetes </td> <td> follow-up 14 weeks<br> n=180/46<br> <br> double blind <br> Japan </td> </tr> <tr> <td> <a href="index.html"> Feinglos, 2005 </a> <br> </td> <td> Liraglutide 0.045–0.75 mg daily<br>  <i>versus</i> <br> Metformin </td> <td> subjects with Type 2 diabetes </td> <td> follow-up 12 weeks<br> n=176/34<br> <br> double blind (not adequate) <br> </td> </tr> <tr> <td> <a href="index.html"> LEAD-3 mono (Garber), 2009 </a> <br> NCT00294723 </td> <td> Liraglutide 1.2–1.8 mg daily <br>  <i>versus</i> <br> Glimepiride 8 mg once daily or Glimepiride 8 mg once daily </td> <td> subjects with type 2 diabetes </td> <td> follow-up 52 weeks (104 weeks)<br> n=498/248<br> <br> double blind <br> North America </td> </tr> <tr> <td> <a href="index.html"> LEAD-2 (Nauck) (vs placebo), 2009 </a> <br> NCT00318461 </td> <td> Liraglutide 1.2–1.8 mg daily<br>  <i>versus</i> <br> Placebo on-top of Metformin </td> <td> subjects previously treated with oral antidiabetes therapy </td> <td> follow-up 26 weeks<br> n=724/121<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> LEAD-1, 0 </a> <br> NCT00318422 </td> <td> Liraglutide 1.2–1.8 mg daily <br>  <i>versus</i> <br> Placebo on-top of sulphonylureas </td> <td> </td> <td> follow-up 26 weeks<br> n=695/115<br> <br> not reported <br> </td> </tr> <tr> <td> <a href="index.html"> LEAD-4, 0 </a> <br> NCT00333151 </td> <td> Liraglutide 1.2–1.8 mg daily<br>  <i>versus</i> <br> Placebo on-top of thiazolidinediones+metformin </td> <td> </td> <td> follow-up 26 weeks<br> n=356/177<br> <br> not reported <br> </td> </tr> <tr> <td> <a href="index.html"> LEAD-5 (vs placebo), 0 </a> <br> NCT00331851 </td> <td> Liraglutide 1.8 mg daily<br>  <i>versus</i> <br> Placebo on-top of sulphonylureas+metformin </td> <td> </td> <td> follow-up 26 weeks<br> n=230/119<br> <br> not reported <br> </td> </tr> <tr> <td> <a href="index.html"> Davis, 2007 </a> <br> NCT00099333 </td> <td> Exenatide 20 µg daily<br>  <i>versus</i> <br> Insulin on-top of sulphonylureas/metformin </td> <td> </td> <td> follow-up 16 weeks<br> n=33/16<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Barnett, 2007 </a> <br> NCT00099619 </td> <td> Exenatide 20 µg daily<br>  <i>versus</i> <br> Insulin </td> <td> </td> <td> follow-up 16 weeks<br> n=136/127<br> Cross over<br> open <br> NA </td> </tr> <tr> <td> <a href="index.html"> Nauck, 2007 </a> <br> NCT00082407 </td> <td> Exenatide 20 µg daily<br>  <i>versus</i> <br> Insulin on-top of sulphonylureas+metformin </td> <td> </td> <td> follow-up 52 weeks<br> n=253/248<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Heine, 2005 </a> <br> </td> <td> Exenatide 20 µg daily<br>  <i>versus</i> <br> Insulin on-top of sulphonylureas+metformin </td> <td> </td> <td> follow-up 26 weeks<br> n=282/267<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> DeFronzo, 2005 </a> <br> NCT00039013 </td> <td> Exenatide 10–20 µg daily<br>  <i>versus</i> <br> Placebo on-top of Metformin </td> <td> patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses </td> <td> follow-up 30 weeks<br> n=223/113<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Zinman, 2007 </a> <br> NCT00099320 </td> <td> Exenatide 20 µg daily<br>  <i>versus</i> <br> Placebo on-top of thiazolidinediones+/-metformin </td> <td> </td> <td> follow-up 16 weeks<br> n=121/112<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Buse, 2004 </a> <br> NCT00039026 </td> <td> Exenatide 20 µg daily<br>  <i>versus</i> <br> Placebo on-top of SU </td> <td> patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy </td> <td> follow-up 30 weeks<br> n=248/129<br> <br> double blind (not adequate) <br> </td> </tr> <tr> <td> <a href="index.html"> Kendall, 2005 </a> <br> NCT00035984 </td> <td> Exenatide 10–20 µg daily<br>  <i>versus</i> <br> Placebo on-top of sulphonylureas+metformin </td> <td> patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy </td> <td> follow-up 30 weeks<br> n=486/247<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Kadowaki (trial 8683), 0 </a> <br> </td> <td> Exenatide 5–10–20 µg daily<br>  <i>versus</i> <br> Placebo on-top of sulphonylureas+/-metformin/thiazolidinediones </td> <td> </td> <td> follow-up 12 weeks<br> n=111/40<br> <br> not reported <br> </td> </tr> <tr> <td> <a href="index.html"> Kim, 2007 </a> <br> NCT00103935 </td> <td> Exenatide 0.8–2 µg daily<br>  <i>versus</i> <br> Placebo on-top of metformin </td> <td> </td> <td> follow-up 15 weeks<br> n=30/15<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Moretto, 2008 </a> <br> NCT00381342 </td> <td> Exenatide 10–20 µg daily<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up 24 weeks<br> n=155/78<br> Parallel groups<br> double blind <br> United States, Puerto Rico, Romania, Russia, India </td> </tr> <tr> <td> <a href="index.html"> Madsbad (vs placebo), 2004 </a> <br> </td> <td> Liraglutide 0.045–0.75 mg daily<br>  <i>versus</i> <br> Placebo </td> <td> </td> <td> follow-up 12 weeks<br> n=135/29<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> LEAD-2 (Nauck) (vs glimepiride), 2009 </a> <br> NCT00318461 </td> <td> Liraglutide 1.2–1.8 mg daily<br>  <i>versus</i> <br> Glimepiride on-top of Metformin </td> <td> </td> <td> follow-up 26 weeks<br> n=724/242<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> LEAD-5 (vs Glargine), 0 </a> <br> NCT00331851 </td> <td> Liraglutide 1.8 mg daily<br>  <i>versus</i> <br> Glargine on-top of sulphonylureas+metformin </td> <td> </td> <td> follow-up 26 weeks<br> n=230/232<br> <br> not reported <br> </td> </tr> <tr> <td> <a href="index.html"> DeFronzo, 2009 </a> <br> </td> <td> saxagliptin (2.5, 5, or 10 mg once daily)<br>  <i>versus</i> <br> placebo </td> <td> patients (A1C > or =7.0 and < or =10.0%) </td> <td> follow-up 24 weeks<br> n=191/179<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Ferrannini, 2009 </a> <br> </td> <td> vildagliptin 50 mg twice daily<br>  <i>versus</i> <br> glimepiride titrated up to 6 mg/day </td> <td> Patients inadequately controlled on metformin monotherapy (HbA(1c) 6.5-8.5%) </td> <td> follow-up 52 weeks<br> n=1396/1393<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Goodman, 2009 </a> <br> </td> <td> ildagliptin 100 mg given in the morning, vildagliptin 100 mg given in the evening<br>  <i>versus</i> <br> placebo </td> <td> patients inadequately controlled with metformin (HbA(1c) 7.5-11%) </td> <td> follow-up 24 weeks<br> n=125/122<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Nauck, 2009 </a> <br> </td> <td> alogliptin 12.5 and 25 mg once daily<br>  <i>versus</i> <br> placebo </td> <td> patients whose HbA(1c) levels were inadequately controlled on metformin alone </td> <td> follow-up 26 weeks<br> n=210/104<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Ristic, 2006 </a> <br> </td> <td> nateglinide plus metformin<br>  <i>versus</i> <br> gliclazide plus metformin </td> <td> Patients with inadequate glucose control on maximal doses of metformin </td> <td> follow-up 24 weeks<br> n=133/129<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Marre, 2002 </a> <br> </td> <td> nateglinide 60 mg, 120 mg before three meals<br>  <i>versus</i> <br> placebo </td> <td> metformin-treated patients with HbA1c between 6.8% and 11% </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Moses, 1999 </a> <br> </td> <td> prestudy dose of metformin with the addition of repaglinide<br>  <i>versus</i> <br> prestudy dose of metformin </td> <td> patients with type 2 diabetes who had inadequate glycemic control (HbA1c > 7.1%) when receiving the antidiabetic agent metformin </td> <td> follow-up 12 weeks<br> n=27/27<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Khanolkar, 2008 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 24 weeks<br> n=25/25<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> scott, 2008 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 18 weeks<br> n=87/91<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Garber, 2006 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 24 weeks<br> n=155/159<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Matthews, 2005 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 52 weeks<br> n=317/313<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Gomez-Perez, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 26 weeks<br> n=36/34<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Fonseca, 2000 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 26 weeks<br> n=113/116<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hamann, 2008 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 52 weeks<br> n=294/301<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Bolli, 2008 </a> <br> </td> <td> vildagliptin (50 mg b.i.d.<br>  <i>versus</i> <br> pioglitazone (30 mg daily </td> <td> </td> <td> follow-up 52 weeks<br> n=295/295<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Scott (vs DPP-4 inhibitor), 2008 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 18 weeks<br> n=87/94<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Nauck (Sulf vs pbo), 2009 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 26 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Nauck (vs GLP-1 analog), 2009 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 26 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Khanolkar, 2008 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 24 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hamann, 2008 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 52 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Nauck, 2007 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 52 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Garber, 2006 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 24 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Ristic, 2006 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 52 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Feinglos, 2005 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 16 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Charpentier, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 20 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Matthews, 2005 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 52 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Li, 2009 </a> <br> </td> <td> Nateglinide<br>  <i>versus</i> <br> repaglinide </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Li, 2007 </a> <br> </td> <td> nateglinide 90 mg three times daily<br>  <i>versus</i> <br> repaglinide 1.0 mg three times daily </td> <td> Chinese patients with type 2 diabetes </td> <td> follow-up 12 weeks<br> n=115/115<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lund, 2007 </a> <br> </td> <td> repaglinide 2 mg thrice daily<br>  <i>versus</i> <br> metformin 1 g twice daily </td> <td> non-obese patients with type 2 diabetes </td> <td> follow-up <br> n=-9/-9<br> Cross over<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> DURATION-3 (Diamant), 2010 </a> <br> NCT00641056 </td> <td> exenatide (2 mg, once-a-week injection)<br>  <i>versus</i> <br> insulin glargine (once-daily injection, starting dose 10 IU, target glucose range 4·0—5·5 mmol/L) </td> <td> adults with type 2 diabetes who had suboptimum glycaemic control despite use of maximum tolerated doses of blood-glucose-lowering drugs for 3 months or longer </td> <td> follow-up 26 weeks<br> n=233/223<br> Parallel groups<br> open (blind analysis) <br> </td> </tr> <tr> <td> <a href="index.html"> DURATION-2 (Bergenstal) (vs sitagliptin), 2010 </a> <br> NCT00637273 </td> <td> 2 mg injected exenatide once weekly plus oral placebo once daily<br>  <i>versus</i> <br> 100 mg oral sitagliptin once daily plus injected placebo once weekly </td> <td> patients treated with metformin </td> <td> follow-up 26 weeks<br> n=-9/-9<br> Parallel groups<br> double blind <br> USA, India, and Mexico </td> </tr> <tr> <td> <a href="index.html"> DURATION-2 (Bergenstal) (vs pioglitazone), 2010 </a> <br> NCT00637273 </td> <td> 2 mg injected exenatide once weekly plus oral placebo once daily <br>  <i>versus</i> <br> 45 mg oral pioglitazone once daily plus injected placebo once weekly </td> <td> </td> <td> follow-up 26 weeks<br> n=170/172<br> <br> double blind <br> USA, India, and Mexico </td> </tr> <tr> <td> <a href="index.html"> Hallsten, 2002 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Pavo, 2003 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hanefeld, 2004 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lawrence, 2004 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Ramachandran, 2004 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Schernthaner, 2004 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Yamanouchi, 2005 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Bailey, 2005 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> EMPIRE (Weissman), 2005 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rosenstock, 1993 </a> <br> </td> <td> glipizide, 2.5 or 5 mg/day<br>  <i>versus</i> <br> glyburide, 1.25 or 2.5 mg/day </td> <td> elderly patients with NIDDM that was controlled for at least 3 months with oral sulfonylurea therapy </td> <td> follow-up 4 months<br> n=139/0<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Birkeland, 1994 </a> <br> </td> <td> glipizide<br>  <i>versus</i> <br> glyburide </td> <td> NIDDM patients </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Draeger, 1996 </a> <br> </td> <td> glimepiride 1 mg daily<br>  <i>versus</i> <br> 2.5 mg glibenclamide </td> <td> type 2 diabetic patients </td> <td> follow-up <br> n=524/520<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Dills, 1996 </a> <br> </td> <td> glimepiride<br>  <i>versus</i> <br> non-micronized glyburide </td> <td> patients with non-insulin dependent diabetes </td> <td> follow-up <br> n=289/288<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Inukai, 2005 </a> <br> </td> <td> glimepiride<br>  <i>versus</i> <br> gliclazide or glibenclamide </td> <td> Japanese type 2 diabetic patients (HbA1C > or = 7.0%), maintained on a conventional SU </td> <td> follow-up 6 months<br> n=172/0<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Horton, 2000 </a> <br> </td> <td> 120 mg nateglinide before meals<br>  <i>versus</i> <br> placebo </td> <td> patients with an HbA1c level between 6.8 and 11.0% during a 4-week placebo run-in </td> <td> follow-up <br> n=179/172<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Hanefeld, 1990 </a> <br> </td> <td> nateglinide at doses of 30 mg, 60 mg, 120 mg, or 180 mg<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up 12 weeks<br> n=229/60<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Saloranta, 2002 </a> <br> </td> <td> nateglinide (30, 60, or 120 mg, with meals).<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes but only moderately elevated fasting plasma glucose (FPG = 7.0-8.3 mmol/liter) </td> <td> follow-up 24 weeks<br> n=675/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Mari, 2005 </a> <br> </td> <td> 30, 60, or 120 mg nateglinide<br>  <i>versus</i> <br> placebo </td> <td> mild type 2 diabetic men and women (fasting glucose 7.0-8.3 mmol/l) on diet treatment </td> <td> follow-up 24 weeks<br> n=108/0<br> Parallel groups<br> double_blind <br> </td> </tr> <tr> <td> <a href="index.html"> Goldberg, 1998 </a> <br> </td> <td> repaglinide<br>  <i>versus</i> <br> placebo </td> <td> type 2 diabetes </td> <td> follow-up <br> n=66/33<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Jovanovic, 2000 </a> <br> </td> <td> repaglinide 1 mg or repaglinide 4 mg<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up 24 weeks<br> n=286/75<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Bech, 2003 </a> <br> </td> <td> repaglinide initiated at 0.5 mg per meal, increased to 1 mg after 4 weeks if fasting plasma glucose exceeded 7.8 mmol/l.<br>  <i>versus</i> <br> placebo </td> <td> pharmacotherapy-naive patients with Type 2 diabetes </td> <td> follow-up 16 weeks<br> n=253/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Moses, 2001 </a> <br> </td> <td> 0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks depending on blood glucose response)<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes considered poorly controlled by diet, but without a history of previous antidiabetic medication </td> <td> follow-up 16 weeks<br> n=408/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Garber, 2002 </a> <br> </td> <td> glyburide 2.5 mg<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes who had failed diet and exercise </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Birkeland, 1994 </a> <br> </td> <td> glipizide<br>  <i>versus</i> <br> glyburide </td> <td> NIDDM patients </td> <td> follow-up 15 months<br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Simonson, 1997 </a> <br> </td> <td> once-daily doses of 5, 20, 40, or 60 mg glipizide GITS<br>  <i>versus</i> <br> placebo </td> <td> NIDDM patients </td> <td> follow-up 4+8 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Vray, 1995 </a> <br> </td> <td> glibenclamide (2.5 mg X 3/d)<br>  <i>versus</i> <br> placebo </td> <td> type 2 diabetic outpatients, 40-70 years of age, treated by diet alone or oral anti-diabetic drugs </td> <td> follow-up <br> n=-9/-9<br> Factorial plan<br> double-blind <br> China </td> </tr> <tr> <td> <a href="index.html"> Testa, 1998 </a> <br> </td> <td> 5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS)<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes mellitus </td> <td> follow-up 12 weeks<br> n=377/192<br> Parallel groups<br> <br> USA </td> </tr> <tr> <td> <a href="index.html"> Cefalu, 1998 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Goldberg, 1996 </a> <br> </td> <td> glimepiride, 1, 4, or 8 mg once daily<br>  <i>versus</i> <br> placebo </td> <td> patients with NIDDM </td> <td> follow-up <br> n=304/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Schade, 1998 </a> <br> </td> <td> glimepiride at individually determined optimal dose (1-8 mg of glimepiride) for 10+12 weeks<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful </td> <td> follow-up <br> n=123/126<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Rosenstock, 1996 </a> <br> </td> <td> glimepiride 8 mg q.d., 4 mg b.i.d., 16 mg q.d., or 8 mg b.i.d<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up 14 weeks<br> n=416/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Luis Bautista, 2003 </a> <br> </td> <td> glimepiride with titration to 2 mg and 4 mg for FPG levels >120 mg/dL<br>  <i>versus</i> <br> placebo </td> <td> Mexican American Patients with type 2 diabetes mellitus </td> <td> follow-up 14 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Garber, 2002 </a> <br> </td> <td> metformin 500 mg<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes who had failed diet and exercise </td> <td> follow-up 20 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Charpentier, 2001 </a> <br> </td> <td> metformin and glimepiride<br>  <i>versus</i> <br> metformin </td> <td> Type 2 diabetic patients aged 35-70 years inadequately controlled by metformin monotherapy 2550 mg daily </td> <td> follow-up <br> n=-9/-9<br> <br> double-blind <br> France </td> </tr> <tr> <td> <a href="index.html"> Willms, 1999 </a> <br> </td> <td> metformin (850 mg b.d.)<br>  <i>versus</i> <br> placebo </td> <td> diabetic patients insufficiently controlled with sulphonylureas alone </td> <td> follow-up 12 weeks<br> n=-9/-9<br> Parallel groups<br> single-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Manzella, 2004 </a> <br> </td> <td> metformin (850 mg twice daily)<br>  <i>versus</i> <br> placebo </td> <td> overweight type 2 diabetic patients </td> <td> follow-up 16 weeks<br> n=60/60<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Del Prato, 2003 </a> <br> </td> <td> metformin (850-2550 mg/day).<br>  <i>versus</i> <br> placebo </td> <td> diet-failed type 2 diabetic patients </td> <td> follow-up <br> n=284/144<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Grant, 1996 </a> <br> </td> <td> metformin 3,000 mg/day or 1,500 mg/day<br>  <i>versus</i> <br> placebo </td> <td> Type II diabetic patients with a BMI > 25 </td> <td> follow-up 6 months<br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Schneider, 1991 </a> <br> </td> <td> metformin<br>  <i>versus</i> <br> placebo </td> <td> patients with NIDDM and hyperlipoproteinemia </td> <td> follow-up 12 weeks<br> n=-9/-9<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Garber, 1997 </a> <br> </td> <td> metformin given at 500, 1000, 1500, 2000, or 2500 mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients with type II diabetes mellitus </td> <td> follow-up 11 weeks<br> n=451/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Lee, 1998 </a> <br> </td> <td> metformin (850 mg)<br>  <i>versus</i> <br> placebo </td> <td> diet-treated NIDDM women with obesity </td> <td> follow-up 24 weeks<br> n=48/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Dornan, 1991 </a> <br> </td> <td> Metformin was administered and built up to a maximum dosage of 1 g three times daily<br>  <i>versus</i> <br> placebo </td> <td> patients with non-insulin-dependent diabetes mellitus treated by diet alone </td> <td> follow-up 8 months<br> n=60/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Hermann, 1991 </a> <br> </td> <td> metformin + glibenclamide<br>  <i>versus</i> <br> metformin </td> <td> patients with non-insulin-dependent diabetes mellitus </td> <td> follow-up 6 months<br> n=-9/-9<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hermann, 1994 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> DeFronzo, 1995 </a> <br> </td> <td> metformin and glyburide<br>  <i>versus</i> <br> metformin </td> <td> patients with non-insulin-dependent diabetes mellitus </td> <td> follow-up 29 weeks<br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> Erle, 1999 </a> <br> </td> <td> low-dose glyburide plus metformin<br>  <i>versus</i> <br> high-dose glyburide alone </td> <td> </td> <td> follow-up <br> n=-9/-9<br> Cross over<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Charpentier, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Marre (ass), 2002 </a> <br> </td> <td> metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) < or = 7 mmol/l<br>  <i>versus</i> <br> metformin 500 mg, </td> <td> patients with Type 2 diabetes mellitus inadequately controlled by metformin monotherapy </td> <td> follow-up 16 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Blonde, 2002 </a> <br> </td> <td> glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg (n = 162)<br>  <i>versus</i> <br> metformin 500 mg </td> <td> patients with inadequate glycaemic control on at least half-maximal dose of sulphonylurea </td> <td> follow-up 16 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Goldstein, </a> <br> </td> <td> glipizide/metformin 5/500 mg tablets<br>  <i>versus</i> <br> metformin 500-mg </td> <td> patients with type 2 DM that is uncontrolled by at least half the maximum labeled daily dose of a sulfonylurea </td> <td> follow-up <br> n=-9/-9<br> Cross over<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Tosi, 2003 </a> <br> </td> <td> metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d<br>  <i>versus</i> <br> metformin (500 to 3,000 mg/d), </td> <td> </td> <td> follow-up 6 months<br> n=-9/-9<br> Cross over<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Garber, 2003 </a> <br> </td> <td> glyburide/metformin<br>  <i>versus</i> <br> metformin </td> <td> patients with type 2 diabetes who had inadequate glycemic control [glycosylated hemoglobin A(1C) (A1C), >7% and <12%) with diet and exercise alone </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lewin, 2010 </a> <br> </td> <td> linagliptin 5 mg<br>  <i>versus</i> <br> placebo (add-on to sulphonylurea) </td> <td> patients with type 2 diabetes and insufficient glycaemic control </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Buse, 2011 </a> <br> NCT00765817 </td> <td> twice-daily 10 µg exenatide injections<br>  <i>versus</i> <br> placebo (on top insulin glargine) </td> <td> Adults with type 2 diabetes and an HbA©û(c) level of 7.1% to 10.5% who were receiving insulin glargine alone or in combination with metformin or pioglitazone (or both agents). </td> <td> follow-up <br> n=138/123<br> Parallel groups<br> double-blind <br> 5 countries </td> </tr> <tr> <td> <a href="index.html"> Protocol 311, </a> <br> </td> <td> glimepiride<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=427/425<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Clark (301), 1997 </a> <br> </td> <td> glimepiride<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=444/208<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Kaneko, 1993 </a> <br> </td> <td> glimepiride<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=62/31<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Study 202, </a> <br> </td> <td> glimepiride<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=122/125<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Sonnenberg, 1997 </a> <br> </td> <td> glimepiride<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=50/48<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Charpentier (301F), </a> <br> </td> <td> glimepiride<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=96/107<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Riddle, 1994 </a> <br> </td> <td> Glimepiride (16 mg/day) plus insulin<br>  <i>versus</i> <br> insulin plus placebo </td> <td> obese patients with type 2 diabetes insufficiently controlled by full dosages of sulphonylureas (glimepiride titrated up to 8mg twice daily and with laboratory-monitored FPG of 10 to 16 mmol/L (180 to 300 mg/dl)) </td> <td> follow-up <br> n=72/73<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Labor, 1990 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Nagi, 1993 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Johnson, 1993 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Tessari, 1994 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Grant, 1996 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Rains, 1988 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Collier, 1989 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Josephkutty, 1990 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hermann, 1991 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Noury, 1991 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Boyd, 1992 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hermann, 1994 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Campbell, 1994 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Chuang, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Landgraf, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Marbury, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Wolffenbuttel, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Madsbad, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Raskin, 2000 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Raskin, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Raskin, 2001 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Landin-Olsson, 1999 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Goldberg, 1998 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Jovanovic, 2000 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Gao, 0 </a> <br> </td> <td> mitiglinide 10 - 20 mg three times daily<br>  <i>versus</i> <br> nateglinide 120 mg three times daily </td> <td> Chinese type 2 diabetes mellitus patients </td> <td> follow-up 20 weeks<br> n=291/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Kaku, 2009 </a> <br> </td> <td> additional mitiglinide 5 or 10 mg tid<br>  <i>versus</i> <br> placebo on top pioglitazone </td> <td> Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy </td> <td> follow-up 16 weeks<br> n=-9/-9<br> Parallel groups<br> multicenter <br> </td> </tr> <tr> <td> <a href="index.html"> Kumashiro, 2007 </a> <br> </td> <td> mitiglinide<br>  <i>versus</i> <br> on top of once daily insulin glargine </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Filozof, 2009 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> COSMIC, 2009 </a> <br> NCT00375388 </td> <td> metformin<br>  <i>versus</i> <br> other usual care treatments </td> <td> type 2 diabetic patients suboptimally controlled on diet or sulfonylurea </td> <td> follow-up 1-year<br> n=7227/1505<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> LEAD-2 (vs MET), 2009 </a> <br> NCT00318461 </td> <td> once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), adding to existing metformin therapy<br>  <i>versus</i> <br> metformin monotherapy and combination therapy of metformin and glimepiride </td> <td> patients with type 2 diabetes previously treated with oral antidiabetes therapy </td> <td> follow-up 26 weeks (104 weeks)<br> n=-9/-9<br> <br> double-blind <br> Europe, Oceania, Africa, Asia and South America </td> </tr> <tr> <td> <a href="index.html"> NN2211-1333, </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Ratner DRI6012, 2010 </a> <br> NCT00299871 </td> <td> subcutaneous lixisenatide doses of 5, 10, 20 or 30 microg once daily or twice daily<br>  <i>versus</i> <br> placebo </td> <td> patients with Type 2 diabetes inadequately controlled with metformin (>= 1000 mg/day) </td> <td> follow-up 13 weeks<br> n=433/109<br> Parallel groups<br> double-blind (nature not volume) <br> multinational </td> </tr> <tr> <td> <a href="index.html"> NCT00085969, </a> <br> NCT00085969 </td> <td> exenatide for 28 days<br>  <i>versus</i> <br> placebo </td> <td> subjects with type 2 diabetes mellitus </td> <td> follow-up 28 days<br> n=99/0<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> NCT00111540, </a> <br> NCT00111540 </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> DeFronzo, 2008 </a> <br> NCT00477581 </td> <td> exenatide subcutaneous injection (5mcg or 10mcg), twice a day <br>  <i>versus</i> <br> sitagliptin </td> <td> subjects with type 2 diabetes mellitus </td> <td> follow-up <br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> Fineman, 2003 </a> <br> </td> <td> exenatide 3 regimen (0.08 micro g/kg) for 28 days<br>  <i>versus</i> <br> placebo </td> <td> patients treated with diet and a sulfonylurea and/or metformin </td> <td> follow-up <br> n=109/0<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Poon, 2005 </a> <br> NCT00044694 </td> <td> exenatide at 2.5, 5.0, 7.5, or 10.0 microg administered b.i.d. for 28 days<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes </td> <td> follow-up 28 days<br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Zinman, 2007 </a> <br> </td> <td> exenatide Subcutaneous abdominal injections of 10 microg twice daily<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes that was suboptimally controlled with TZD treatment (with or without metformin) </td> <td> follow-up 16 weeks<br> n=121/112<br> Parallel groups<br> double-blind <br> Canada, Spain, and the United States </td> </tr> <tr> <td> <a href="index.html"> Trial 8078, </a> <br> </td> <td> exenatide<br>  <i>versus</i> <br> Insulin Glargine </td> <td> Patients with Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin Is the Next Appropriate Therapy </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Schwartz, 2008 </a> <br> </td> <td> SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) for 14 days<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes with inadequate glycemic control, despite metformin with or without a TZD </td> <td> follow-up 2 weeks<br> n=17/13<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> 9607, 2009 </a> <br> NCT00324363 </td> <td> exenatide (BID, before the morning and evening meals) <br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes and inadequate glycemic control taking metformin alone or Met and sulfonylureas </td> <td> follow-up 16 weeks<br> n=234/232<br> <br> double-blind <br> 4 countries </td> </tr> <tr> <td> <a href="index.html"> Exenatide Trial 10749, </a> <br> </td> <td> exenatide (10 ìg twice daily) administered subcutaneously before lunch and dinner<br>  <i>versus</i> <br> exenatide (10 ìg twice daily) administered subcutaneously before breakfast and dinner </td> <td> patients with type 2 Diabetes using oral antidiabetic therapy </td> <td> follow-up <br> n=187/190<br> Parallel groups<br> open <br> 2 countries </td> </tr> <tr> <td> <a href="index.html"> 9698, </a> <br> </td> <td> exenatide twice daily 5 et 10 µg for 24 weeks<br>  <i>versus</i> <br> placebo </td> <td> Drug-Naive Patients with Type 2 Diabetes </td> <td> follow-up 24 weeks<br> n=155/78<br> Parallel groups<br> double-blind <br> 4 countries </td> </tr> <tr> <td> <a href="index.html"> PPAR, </a> <br> NCT00212004 </td> <td> pioglitazone<br>  <i>versus</i> <br> sulfonylurea agents </td> <td> diabetes patients with a history of prior myocardial infarction </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> <br> Japan </td> </tr> <tr> <td> <a href="index.html"> TIDE, </a> <br> NCT00879970 </td> <td> pioglitazone or rosiglitazone<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease </td> <td> follow-up <br> n=16000/0<br> Factorial plan<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> LEADER, </a> <br> NCT01179048 </td> <td> Maximum dose of 1.8 mg liraglutide, injected subcutaneously once daily<br>  <i>versus</i> <br> placebo </td> <td> subjects with type 2 diabetes </td> <td> follow-up <br> n=-9/-9<br> <br> double-blind <br> Africa, Asia, Europe, North and South America </td> </tr> <tr> <td> <a href="index.html"> GetGoal-M-As, 0 </a> <br> NCT01169779 </td> <td> Lixisenatide (Titration phase: 10 µg maintenance phase: 20 µg, add-on treatment to metformin with or without sulfonylurea<br>  <i>versus</i> <br> add-on treatment to metformin with or without sulfonylurea </td> <td> </td> <td> follow-up 24 weeks<br> n=-9/-9<br> <br> double-blind <br> China </td> </tr> <tr> <td> <a href="index.html"> EFC11319, 0 </a> <br> NCT01147250 </td> <td> Lixisenatide 20 µg one daily<br>  <i>versus</i> <br> placebo </td> <td> type 2 diabetic patients who experienced an acute coronary syndrome </td> <td> follow-up <br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> EFC10781, 0 </a> <br> NCT00975286 </td> <td> Lixisenatide as an add-on treatment to insulin glargine and metformin<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes insufficiently controlled with insulin glargine and metformin </td> <td> follow-up 24 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> EFC10780, 2010 </a> <br> NCT00976937 </td> <td> Lixisenatide titrated 15-20 µg once daily<br>  <i>versus</i> <br> Sitagliptin (add-on to Metformin) </td> <td> Obese Type 2 Diabetic Patients Younger Than 50 </td> <td> follow-up 24 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> WW </td> </tr> <tr> <td> <a href="index.html"> BC21893, 0 </a> <br> NCT00909597 </td> <td> taspoglutide 10mg sc weekly, or taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly<br>  <i>versus</i> <br> pioglitazone 45mg/day po after 4 weeks of pioglitazone 30mg/day po </td> <td> patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy </td> <td> follow-up 24 months<br> n=-9/-9<br> parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> NC25113, 0 </a> <br> NCT01018173 </td> <td> taspoglutide subcutaneously (sc) 10mg weekly for 4 weeks followed by 20mg sc weekly in addition to background anti-hyperglycemic medication and standard of care treatment for cardiovascular disease<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up <br> n=-9/-9<br> parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> BC21625, 0 </a> <br> NCT00717457 </td> <td> taspoglutide<br>  <i>versus</i> <br> exenatide </td> <td> patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both </td> <td> follow-up <br> n=-9/-9<br> parallel groups<br> open <br> USA </td> </tr> <tr> <td> <a href="index.html"> BC22092, 0 </a> <br> NCT00823992 </td> <td> taspoglutide (10mg sc once weekly for 4 weeks followed by 20mg once weekly) in addition to their prescribed, pre-existing metformin therapy<br>  <i>versus</i> <br> placebo </td> <td> obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy </td> <td> follow-up <br> n=-9/-9<br> parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> BC20750, 0 </a> <br> NCT00744926 </td> <td> taspoglutide 10mg sc once weekly, or taspoglutide 20mg sc once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes mellitus inadequately controlled with diet and exercise </td> <td> follow-up <br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> BC21713 (vs placebo), 0 </a> <br> NCT00754988 </td> <td> taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly),<br>  <i>versus</i> <br> placebo or sitagliptin 100mg once daily in addition to their continued prestudy metformin treatment </td> <td> patients with type 2 diabetes mellitus inadequately controlled with metformin </td> <td> follow-up <br> n=-9/-9<br> parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> BC20963, 0 </a> <br> NCT00744367 </td> <td> taspoglutide 10mg once weekly, taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)<br>  <i>versus</i> <br> placebo in addition to their continued stable metformin plus pioglitazone treatment </td> <td> patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone </td> <td> follow-up 24 weeks<br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> ZC22565, 0 </a> <br> NCT01051011 </td> <td> taspoglutide 10mg subcutaneously (sc) weekly, or taspoglutide 10mg sc weekly for 4 weeks followed by 20mg sc weekly<br>  <i>versus</i> <br> insulin glargine at an initial dose of 10 international units sc daily </td> <td> insulin-naïve patients with type 2 diabetes mellitus inadequately controlled on merformin and sulfonylurea combination therapy </td> <td> follow-up <br> n=-9/-9<br> parallel groups<br> open <br> China </td> </tr> <tr> <td> <a href="index.html"> BC20965, 0 </a> <br> NCT00755287 </td> <td> taspoglutide (10 mg once weekly, or 10mg once weekly for 4 weeks followed by 20mg once weekly)<br>  <i>versus</i> <br> insulin glargine (starting dose 10 IU/day) in addition to continued prestudy metformin treatment </td> <td> patients with insulin-naive type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea combination therapy </td> <td> follow-up 2 years<br> n=-9/-9<br> <br> open <br> USA </td> </tr> <tr> <td> <a href="index.html"> CAROLINA, 0 </a> <br> NCT01243424 </td> <td> linagliptin<br>  <i>versus</i> <br> glimepiride 1-4 mg QD </td> <td> patients with type 2 diabetes at elevated cardiovascular risk receiving usual care </td> <td> follow-up <br> n=-9/-9<br> parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> linagliptin 1218.61, 0 </a> <br> NCT00996658 </td> <td> Linagliptin (5 mg once daily)<br>  <i>versus</i> <br> placebo (add on therapy to metformin in combination with pioglitazone) </td> <td> Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> linagliptin 1218.65, 0 </a> <br> NCT01215097 </td> <td> 5 mg of Linagliptin administered orally once daily<br>  <i>versus</i> <br> placebo (on top metformin) </td> <td> patients with type 2 diabetes and insufficient glycaemic control with metformin </td> <td> follow-up 24 weeks<br> n=-9/-9<br> parallel groups<br> double-blind <br> China </td> </tr> <tr> <td> <a href="index.html"> linagliptin 1218.62, 0 </a> <br> NCT01012037 </td> <td> linagliptin low dose 2.5 mg twice daily<br>  <i>versus</i> <br> linagliptin medium dose 5 mg once daily </td> <td> patients with type 2 diabetes mellitus with insufficient glycaemic control with metformin </td> <td> follow-up 12 weeks<br> n=-9/-9<br> parallel groups<br> double-blind <br> Belgium </td> </tr> <tr> <td> <a href="index.html"> linagliptine 1218.50, 0 </a> <br> NCT00740051 </td> <td> Linagliptin<br>  <i>versus</i> <br> Placebo </td> <td> patients for whom metformin therapy is inappropriate (intolerability, contraindication) </td> <td> follow-up 18 weeks<br> n=-9/-9<br> parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> linagliptine 1218.35, 0 </a> <br> NCT00819091 </td> <td> linagliptine 5 mg po once daily<br>  <i>versus</i> <br> placebo (on top sulfonylurea) </td> <td> Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea </td> <td> follow-up 18 weeks<br> n=-9/-9<br> parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> linagliptine 1218.6, 0 </a> <br> NCT00309608 </td> <td> Linagliptin (1, 5, or 10 mg taken once daily)<br>  <i>versus</i> <br> placebo (on top Metformin ) </td> <td> patients with type 2 diabetes mellitus who are not at goal with their HbA1c levels </td> <td> follow-up 12 weeks<br> n=-9/-9<br> parallel groups<br> double-blind <br> France </td> </tr> <tr> <td> <a href="index.html"> linagliptin1218.5, 0 </a> <br> NCT00328172 </td> <td> linagliptin (0.5, 2.5 and 5 mg daily)<br>  <i>versus</i> <br> placebo </td> <td> patients with Type 2 diabetes and insufficient glycemic control </td> <td> follow-up 12 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> linagliptin 1218.16, 0 </a> <br> NCT00621140 </td> <td> linagliptin<br>  <i>versus</i> <br> placebo </td> <td> Type 2 Diabetic Patients With Insufficient Glycemic Control </td> <td> follow-up 24 weeks<br> n=-9/-9<br> parallel groups<br> double-blind <br> Croatia </td> </tr> <tr> <td> <a href="index.html"> linagliptine 1218.20, 0 </a> <br> NCT00622284 </td> <td> BI 1356 (5.0 mg daily) add-on therapy to preferably > 1500 mg metformin<br>  <i>versus</i> <br> glimepiride add-on therapy to preferably > 1500 mg metformin </td> <td> type 2 diabetes mellitus with insufficient glycaemic control with metformin </td> <td> follow-up 104 weeks<br> n=-9/-9<br> parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> linagliptin 1264.3, 0 </a> <br> NCT01183013 </td> <td> linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) linagliptine<br>  <i>versus</i> <br> pioglitazone </td> <td> </td> <td> follow-up 30 weeks<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> linagliptin 1218.18, 0 </a> <br> NCT00602472 </td> <td> linagliptin add-on therapy to metformin in combination with a sulphonylurea<br>  <i>versus</i> <br> placebo add-on therapy to metformin in combination with a sulphonylurea </td> <td> type 2 diabetes mellitus with insufficient glycaemic control with metformin in combination with a sulphonylurea </td> <td> follow-up 24 weeks<br> n=-9/-9<br> parallel groups<br> <br> Argentina </td> </tr> <tr> <td> <a href="index.html"> linagliptin 1218.46, 0 </a> <br> NCT00798161 </td> <td> <br>  <i>versus</i> <br> </td> <td> drug naive or previously treated type 2 diabetic patients with insufficient glycaemic control </td> <td> follow-up 24 weeks<br> n=-9/-9<br> parallel groups<br> <br> Canada </td> </tr> <tr> <td> <a href="index.html"> GetGoal-X, 0 </a> <br> NCT00707031 </td> <td> AVE0010 in association with metformin<br>  <i>versus</i> <br> exenatide in association with metformin </td> <td> type 2 diabetes </td> <td> follow-up 24 weeks<br> n=-9/-9<br> parallel groups<br> open <br> USA </td> </tr> <tr> <td> <a href="index.html"> H8O-MC-GWDE, 0 </a> <br> NCT01029886 </td> <td> exenatide once weekly for 26 weeks<br>  <i>versus</i> <br> once-daily liraglutide for 26 weeks </td> <td> </td> <td> follow-up 36 weeks<br> n=-9/-9<br> <br> open <br> argentina </td> </tr> <tr> <td> <a href="index.html"> 114179, 0 </a> <br> NCT01128894 </td> <td> weekly albiglutide subcutaneous injection<br>  <i>versus</i> <br> liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information </td> <td> subjects with type 2 diabetes </td> <td> follow-up <br> n=-9/-9<br> <br> open <br> USA </td> </tr> <tr> <td> <a href="index.html"> LIBRA, 0 </a> <br> NCT01270789 </td> <td> <br>  <i>versus</i> <br> </td> <td> patients with T2DM </td> <td> follow-up 1 year<br> n=-9/-9<br> <br> double-blind <br> Canada </td> </tr> <tr> <td> <a href="index.html"> NN2211-1800, 0 </a> <br> NCT00943501 </td> <td> self-injection by children subcutaneously over 5 weeks<br>  <i>versus</i> <br> </td> <td> children with type 2 diabetes </td> <td> follow-up <br> n=-9/-9<br> <br> double-blind <br> USA, Europe </td> </tr> <tr> <td> <a href="index.html"> EAGLE, 0 </a> <br> NCT01117350 </td> <td> Liraglutide (6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg))<br>  <i>versus</i> <br> Insulin Glargine (100 Units/mL solution for injection in a pre-filled SoloStar pen) </td> <td> Type 2 diabetic patients failing lifestyle management and oral agents </td> <td> follow-up <br> n=-9/-9<br> <br> open <br> USA </td> </tr> <tr> <td> <a href="index.html"> NCT01234649, 0 </a> <br> NCT01234649 </td> <td> addition of liraglutide to metformin<br>  <i>versus</i> <br> metformin alone </td> <td> at-risk overweight/obese women with prior gestational diabetes mellitus </td> <td> follow-up <br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> NN2211-3619, 0 </a> <br> NCT01206101 </td> <td> <br>  <i>versus</i> <br> </td> <td> Type 1 Diabetes Undergoing Islet Cell Transplantation </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> NN8022-1923, 0 </a> <br> NCT00781937 </td> <td> Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (s.c.) injection, once daily <br>  <i>versus</i> <br> placebo </td> <td> obese non-diabetic subjects or overweight subjects who have medical problems such as hypertension or dyslipidaemia </td> <td> follow-up 56 weeks<br> n=-9/-9<br> <br> double-blind <br> North America </td> </tr> <tr> <td> <a href="index.html"> NN8022-1922, 0 </a> <br> NCT01272232 </td> <td> Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks in addition to subject's pre-trial background treatment <br>  <i>versus</i> <br> placebo </td> <td> overweight or obese subjects with type 2 diabetes </td> <td> follow-up 56 weeks<br> n=-9/-9<br> <br> double-blind <br> Afria, Asia, Europe and the United States of America </td> </tr> <tr> <td> <a href="index.html"> MK-0431-403, 0 </a> <br> NCT01296412 </td> <td> Liraglutide + metformin<br>  <i>versus</i> <br> Sitagliptin + metformin </td> <td> patients with Type 2 Diabetes that is not adequately controlled with metformin alone </td> <td> follow-up <br> n=-9/-9<br> parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> BP21572, 0 </a> <br> NCT00809705 </td> <td> 10mg Taspoglutide sc weekly for 12 weeks b)10mg Taspoglutide sc weekly for 4 weeks followed by 20mg Taspoglutide sc weekly for 8 weeks<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes </td> <td> follow-up 12 weeks<br> n=-9/-9<br> <br> double-blind <br> germany </td> </tr> <tr> <td> <a href="index.html"> GETGOAL-MONO, 0 </a> <br> NCT00688701 </td> <td> AVE0010 in monotherapy<br>  <i>versus</i> <br> lixisenatide </td> <td> Type 2 diabetes mellitus not treated with any antidiabetic agent </td> <td> follow-up 12 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> GETGOAL-S, 0 </a> <br> NCT00713830 </td> <td> AVE0010 in association with sulfonylurea without or with metformin<br>  <i>versus</i> <br> placebo </td> <td> patients with type 2 diabetes not adequately controlled with sulfonylurea </td> <td> follow-up 24 weeks<br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> GETGOAL-F1, 0 </a> <br> NCT00763451 </td> <td> AVE0010 in association with metformin<br>  <i>versus</i> <br> placebo </td> <td> Type 2 diabetes mellitus insufficiently controlled with metformin </td> <td> follow-up 24 weeks<br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> GETGOAL-L, 0 </a> <br> NCT00715624 </td> <td> AVE0010 in association with basal insulin with or without metformin<br>  <i>versus</i> <br> placebo </td> <td> Type 2 diabetes mellitus insufficiently controlled with basal insulin with or without metformin </td> <td> follow-up 24 weeks<br> n=-9/-9<br> <br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> GETGOAL-P, 0 </a> <br> NCT00763815 </td> <td> AVE0010 in association with pioglitazone with or without metformin<br>  <i>versus</i> <br> placebo </td> <td> Type 2 diabetes mellitus insufficiently controlled with pioglitazone with or without metformin </td> <td> follow-up 24 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> GETGOAL-MONO Japan LTS, 0 </a> <br> NCT00905255 </td> <td> AVE0010 once daily treatment in monotherapy<br>  <i>versus</i> <br> usual care </td> <td> type 2 diabetes patients </td> <td> follow-up 24-76 weeks<br> n=-9/-9<br> Parallel groups<br> open <br> Japan </td> </tr> <tr> <td> <a href="index.html"> GETGOAL-M, 0 </a> <br> NCT00712673 </td> <td> AVE0010 in association with metformin<br>  <i>versus</i> <br> </td> <td> Type 2 diabetes mellitus insufficiently controlled with metformin </td> <td> follow-up 24 weeks<br> n=-9/-9<br> Parallel groups<br> double-blind <br> USA </td> </tr> <tr> <td> <a href="index.html"> GETGOAL-L-ASIA, 0 </a> <br> NCT00866658 </td> <td> 24 weeks of AVE0010<br>  <i>versus</i> <br> placebo on Top of Basal Insulin +/- Sulfonylurea </td> <td> </td> <td> follow-up 24 weeks<br> n=-9/-9<br> <br> double-blind <br> Japan </td> </tr> </table> <h2>References</h2> <p> <b>PROactive, 2005 : </b> Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, PoSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <i>Lancet 2005 Oct 8;366:1279-89</i> [PMID 16214598] </p> <p> <b>Wang, 2005 : </b> Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X, Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. <i>Metabolism 2005;54:590-7.</i> [PMID 15877288] 10.1016/j.metabol.2004.11.017 </p> <p> <b>PERISCOPE, 2008 : </b> Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EMComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. <i>JAMA 2008 Apr 2;299:1561-73</i> [PMID 18378631] </p> <p> <b>DREAM, : </b> Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RREffect of ramipril on the incidence of diabetes. <i>N Engl J Med 2006;355:1551-62</i> [PMID 16980380] </p> <p> <b>DREAM, : </b> Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RREffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. <i>Lancet 2006;368:1096-105</i> [PMID 16997664] </p> <p> <b>DREAM, : </b> Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf SEffects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. <i>Diabetes Care 2008;31:1007-14</i> [PMID 18268075] </p> <p> <b>DREAM, : </b> Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue JRationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. <i>Diabetologia 2004;47:1519-27</i> [PMID 15322749] </p> <p> <b>ADOPT, 2006 : </b> Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti GGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <i>N Engl J Med 2006;355:2427-43</i> [PMID 17145742] </p> <p> <b>ADOPT, 2006 : </b> Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti GRosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care 2008;31:845-51</i> [PMID 18223031] </p> <p> <b>RECORD, 2009 : </b> Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PDEffect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). <i>Cardiovasc Diabetol 2008 Apr 24;7:10</i> [PMID 18435852] </p> <p> <b>RECORD, 2009 : </b> Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet 2009 Jun 5;:</i> [PMID 19501900] 10.1016/S0140-6736(09)60953-3 </p> <p> <b>RECORD, 2009 : </b> Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PDHeart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. <i>Eur Heart J 2010;:</i> [PMID 20118174] 10.1093/eurheartj/ehp604 </p> <p> <b>UKPDS (vs SU or INS), 0 : </b> Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. <i>Lancet 1998;352:854-65</i> [PMID 9742977] </p> <p> <b>UKPDS (v Conven), 0 : </b> Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. <i>Lancet 1998;352:854-65</i> [PMID 9742977] </p> <p> <b>DeFronzo (vs glyburide), 1995 : </b> DeFronzo RA, Goodman AMEfficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. <i>N Engl J Med 1995;333:541-9</i> [PMID 7623902] </p> <p> <b>Horton (vs PBO), 2000 : </b> Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen SNateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. <i>Diabetes Care 2000;23:1660-5</i> [PMID 11092289] </p> <p> <b>Hallsten (vs PBO), 2002 : </b> Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila PRosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. <i>Diabetes 2002;51:3479-85</i> [PMID 12453903] </p> <p> <b>Teupe, 1991 : </b> Teupe B, Bergis KProspective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. <i>Diabete Metab 1991;17:213-7</i> [PMID 1936479] </p> <p> <b>DeFronzo (vs PBO), 1995 : </b> DeFronzo RA, Goodman AMEfficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. <i>N Engl J Med 1995 Aug 31;333:541-9</i> [PMID 7623902] </p> <p> <b>APPROACH, 2008 : </b> Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJAssessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. <i>Am Heart J 2008;156:1074-9</i> [PMID 19033001] </p> <p> <b>APPROACH, 2008 : </b> Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RWEffect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. <i>Circulation 2010;121:1176-87</i> [PMID 20194881] 10.1161/CIRCULATIONAHA.109.881003 </p> <p> <b>HOME, 2009 : </b> Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, Stehouwer CDLong-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. <i>Arch Intern Med 2009;169:616-25</i> [PMID 19307526] </p> <p> <b>Aschner, 2006 : </b> Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DEEffect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. <i>Diabetes Care 2006;29:2632-7</i> [PMID 17130196] 10.2337/dc06-0703 </p> <p> <b>Goldstein, 2007 : </b> Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DEEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. <i>Diabetes Care 2007;30:1979-87</i> [PMID 17485570] 10.2337/dc07-0627 </p> <p> <b>Hanefeld, 2007 : </b> Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PPOnce-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. <i>Curr Med Res Opin 2007;23:1329-39</i> [PMID 17559733] 10.1185/030079907X188152 </p> <p> <b>Nonaka, 2008 : </b> Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PPEfficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. <i>Diabetes Res Clin Pract 2008;79:291-8</i> [PMID 17933414] 10.1016/j.diabres.2007.08.021 </p> <p> <b>Raz, 2006 : </b> Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami HEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. <i>Diabetologia 2006;49:2564-71</i> [PMID 17001471] 10.1007/s00125-006-0416-z </p> <p> <b>Scott* (sit vs pbo), 2007 : </b> Scott R, Wu M, Sanchez M, Stein PEfficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. <i>Int J Clin Pract 2007;61:171-80</i> [PMID 17156104] 10.1111/j.1742-1241.2006.01246.x </p> <p> <b>Goldstein (sit vs met), 2007 : </b> Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DEEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. <i>Diabetes Care 2007;30:1979-87</i> [PMID 17485570] 10.2337/dc07-0627 </p> <p> <b>Scott* (sit vs glipi), 2007 : </b> Scott R, Wu M, Sanchez M, Stein PEfficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. <i>Int J Clin Pract 2007;61:171-80</i> [PMID 17156104] 10.1111/j.1742-1241.2006.01246.x </p> <p> <b>Charbonnel, 2006 : </b> Charbonnel B, Karasik A, Liu J, Wu M, Meininger GEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. <i>Diabetes Care 2006;29:2638-43</i> [PMID 17130197] 10.2337/dc06-0706 </p> <p> <b>Goldstein (sit+met vs met), 2007 : </b> Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DEEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. <i>Diabetes Care 2007;30:1979-87</i> [PMID 17485570] 10.2337/dc07-0627 </p> <p> <b>Hermansen, 2007 : </b> Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein PEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. <i>Diabetes Obes Metab 2007;9:733-45</i> [PMID 17593236] 10.1111/j.1463-1326.2007.00744.x </p> <p> <b>Nauck, 2007 : </b> Nauck MA, Meininger G, Sheng D, Terranella L, Stein PPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. <i>Diabetes Obes Metab 2007;9:194-205</i> [PMID 17300595] 10.1111/j.1463-1326.2006.00704.x </p> <p> <b>Rosenstock (sit on top pio vs pbo), 2006 : </b> Ristic S, Byiers S, Foley J, Holmes DImproved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. <i>Diabetes Obes Metab 2005;7:692-8</i> [PMID 16219012] 10.1111/j.1463-1326.2005.00539.x </p> <p> <b>Scott** (sit vs pbo on top met), 2007 : </b> Scott R, Loeys T, Davies MJ, Engel SSEfficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. <i>Diabetes Obes Metab 2008;10:959-69</i> [PMID 18201203] 10.1111/j.1463-1326.2007.00839.x </p> <p> <b>Dejager, 2007 : </b> Dejager S, Razac S, Foley JE, Schweizer AVildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. <i>Horm Metab Res 2007;39:218-23</i> [PMID 17373638] 10.1055/s-2007-970422 </p> <p> <b>Mimori, 2006 : </b> MimoriN,Terao S,Holmes D. <i>Diabetes 2006;55(suppl 1):A125 </i> [PMID ] </p> <p> <b>Pi-Sunyer, 2007 : </b> Pi-Sunyer FX, Schweizer A, Mills D, Dejager SEfficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. <i>Diabetes Res Clin Pract 2007;76:132-8</i> [PMID 17223217] 10.1016/j.diabres.2006.12.009 </p> <p> <b>Pratley, 2006 : </b> Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes DTwelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. <i>Horm Metab Res 2006;38:423-8</i> [PMID 16823726] 10.1055/s-2006-944546 </p> <p> <b>Ristic, 2005 : </b> Ristic S, Byiers S, Foley J, Holmes DImproved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. <i>Diabetes Obes Metab 2005;7:692-8</i> [PMID 16219012] 10.1111/j.1463-1326.2005.00539.x </p> <p> <b>Scherbaum, 2008 : </b> Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JECharacterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. <i>J Clin Endocrinol Metab 2008;93:103-9</i> [PMID 17925336] 10.1210/jc.2007-1639 </p> <p> <b>Rosenstock* (vilda vs rosi), 2007 : </b> Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer AComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. <i>Diabetes Care 2007;30:217-23</i> [PMID 17259484] 10.2337/dc06-1815 </p> <p> <b>Rosenstock** (vilda vs pio), 2007 : </b> Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager SEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. <i>Diabetes Obes Metab 2007;9:175-85</i> [PMID 17300593] 10.1111/j.1463-1326.2006.00698.x </p> <p> <b>Schweizer, 2007 : </b> Schweizer A, Couturier A, Foley JE, Dejager SComparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. <i>Diabet Med 2007;24:955-61</i> [PMID 17509069] 10.1111/j.1464-5491.2007.02191.x </p> <p> <b>Ahren, 2004 : </b> Ahrén B, Gomis R, Standl E, Mills D, Schweizer ATwelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. <i>Diabetes Care 2004;27:2874-80</i> [PMID 15562200] </p> <p> <b>Bolli, 2008 : </b> Bolli G, Dotta F, Rochotte E, Cohen SEEfficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. <i>Diabetes Obes Metab 2008;10:82-90</i> [PMID 18034842] 10.1111/j.1463-1326.2007.00820.x </p> <p> <b>Bosi, 2007 : </b> Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. <i>Diabetes Care 2007;30:890-5</i> [PMID 17277036] 10.2337/dc06-1732 </p> <p> <b>Fonseca, 2007 : </b> Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager SAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. <i>Diabetologia 2007;50:1148-55</i> [PMID 17387446] 10.1007/s00125-007-0633-0 </p> <p> <b>Garber, 2007 : </b> Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager SVildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. <i>Diabetes Obes Metab 2007;9:166-74</i> [PMID 17300592] 10.1111/j.1463-1326.2006.00684.x </p> <p> <b>Rosenstock** (vilda + pio vs pio), 2007 : </b> Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager SEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. <i>Diabetes Obes Metab 2007;9:175-85</i> [PMID 17300593] 10.1111/j.1463-1326.2006.00698.x </p> <p> <b>Madsbad (vs Glimepiride), 2004 : </b> Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DRImproved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. <i>Diabetes Care 2004;27:1335-42</i> [PMID 15161785] </p> <p> <b>Vilsboll, 2008 : </b> Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad SLiraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. <i>Diabet Med 2008;25:152-6</i> [PMID 18201212] 10.1111/j.1464-5491.2007.02333.x </p> <p> <b>Seino, 2008 : </b> Seino Y, Rasmussen MF, Zdravkovic M, Kaku KDose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. <i>Diabetes Res Clin Pract 2008;81:161-8</i> [PMID 18495285] 10.1016/j.diabres.2008.03.018 </p> <p> <b>Feinglos, 2005 : </b> Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago OEffects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. <i>Diabet Med 2005;22:1016-23</i> [PMID 16026367] 10.1111/j.1464-5491.2005.01567.x </p> <p> <b>LEAD-3 mono (Garber), 2009 : </b> Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode BLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. <i>Lancet 2009;373:473-81</i> [PMID 18819705] 10.1016/S0140-6736(08)61246-5 </p> <p> <b>LEAD-2 (Nauck) (vs placebo), 2009 : </b> Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DREfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. <i>Diabetes Care 2009;32:84-90</i> [PMID 18931095] 10.2337/dc08-1355 </p> <p> <b>LEAD-2 (Nauck) (vs placebo), 2009 : </b> Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde LLong-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. <i>Cardiovasc Diabetol 2009;8:12</i> [PMID 19245711] 10.1186/1475-2840-8-12 </p> <p> <b>LEAD-2 (Nauck) (vs placebo), 2009 : </b> Nauck M, Marre MAdding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. <i>Postgrad Med 2009;121:5-15</i> [PMID 19491535] 10.3810/pgm.2009.05.1997 </p> <p> <b>LEAD-4, 0 : </b> Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, , Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). <i>Diabetes Care 2009;32:1224-30.</i> [PMID 19289857] 10.2337/dc08-2124 </p> <p> <b>Davis, 2007 : </b> Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RGExploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. <i>Diabetes Care 2007;30:2767-72</i> [PMID 17595353] 10.2337/dc06-2532 </p> <p> <b>Barnett, 2007 : </b> Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann METolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. <i>Clin Ther 2007;29:2333-48</i> [PMID 18158075] 10.1016/j.clinthera.2007.11.006 </p> <p> <b>Nauck, 2007 : </b> Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann MA comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia 2007;50:259-67</i> [PMID 17160407] 10.1007/s00125-006-0510-2 </p> <p> <b>Heine, 2005 : </b> Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RGExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. <i>Ann Intern Med 2005;143:559-69</i> [PMID 16230722] </p> <p> <b>DeFronzo, 2005 : </b> DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron ADEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. <i>Diabetes Care 2005;28:1092-100</i> [PMID 15855572] </p> <p> <b>DeFronzo, 2005 : </b> Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DMInterim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. <i>Diabetes Obes Metab 2006;8:436-47</i> [PMID 16776751] 10.1111/j.1463-1326.2006.00602.x </p> <p> <b>DeFronzo, 2005 : </b> Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DDLong-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. <i>Diabetes Obes Metab 2006;8:419-28</i> [PMID 16776749] 10.1111/j.1463-1326.2006.00589.x </p> <p> <b>Zinman, 2007 : </b> Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RGThe effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. <i>Ann Intern Med 2007;146:477-85</i> [PMID 17404349] </p> <p> <b>Buse, 2004 : </b> Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron ADEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. <i>Diabetes Care 2004;27:2628-35</i> [PMID 15504997] </p> <p> <b>Buse, 2004 : </b> Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DGExenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. <i>Diabetes Metab Res Rev 2006;22:483-91</i> [PMID 16634116] 10.1002/dmrr.646 </p> <p> <b>Buse, 2004 : </b> Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DMInterim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. <i>Diabetes Obes Metab 2006;8:436-47</i> [PMID 16776751] 10.1111/j.1463-1326.2006.00602.x </p> <p> <b>Kendall, 2005 : </b> Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron ADEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. <i>Diabetes Care 2005;28:1083-91</i> [PMID 15855571] </p> <p> <b>Kadowaki (trial 8683), 0 : </b> Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RGExenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. <i>Endocr J 2009;56:415-24</i> [PMID 19194050] </p> <p> <b>Kim, 2007 : </b> Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor KEffects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. <i>Diabetes Care 2007;30:1487-93</i> [PMID 17353504] 10.2337/dc06-2375 </p> <p> <b>Moretto, 2008 : </b> Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RGEfficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. <i>Clin Ther 2008;30:1448-60</i> [PMID 18803987] 10.1016/j.clinthera.2008.08.006 </p> <p> <b>Madsbad (vs placebo), 2004 : </b> Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DRImproved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. <i>Diabetes Care 2004;27:1335-42</i> [PMID 15161785] </p> <p> <b>LEAD-2 (Nauck) (vs glimepiride), 2009 : </b> Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DREfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. <i>Diabetes Care 2009;32:84-90</i> [PMID 18931095] 10.2337/dc08-1355 </p> <p> <b>LEAD-5 (vs Glargine), 0 : </b> Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R, , Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. <i>Diabetologia 2009;52:2046-55.</i> [PMID 19688338] 10.1007/s00125-009-1472-y </p> <p> <b>LEAD-5 (vs Glargine), 0 : </b> Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó RLiraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. <i>Diabetologia 2009 Oct;52:2046-55</i> [PMID 19688338] </p> <p> <b>LEAD-5 (vs Glargine), 0 : </b> Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde LLong-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. <i>Cardiovasc Diabetol 2009 Feb 26;8:12</i> [PMID 19245711] </p> <p> <b>DeFronzo, 2009 : </b> DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RSThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. <i>Diabetes Care 2009;32:1649-55</i> [PMID 19478198] 10.2337/dc08-1984 </p> <p> <b>Ferrannini, 2009 : </b> Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager SFifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. <i>Diabetes Obes Metab 2009;11:157-66</i> [PMID 19125777] 10.1111/j.1463-1326.2008.00994.x </p> <p> <b>Goodman, 2009 : </b> Goodman M, Thurston H, Penman JEfficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. <i>Horm Metab Res 2009;41:368-73</i> [PMID 19221978] 10.1055/s-0028-1104604 </p> <p> <b>Nauck, 2009 : </b> Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki QEfficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. <i>Int J Clin Pract 2009;63:46-55</i> [PMID 19125992] 10.1111/j.1742-1241.2008.01933.x </p> <p> <b>Ristic, 2006 : </b> Ristic S, Collober-Maugeais C, Pecher E, Cressier FComparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. <i>Diabet Med 2006;23:757-62</i> [PMID 16842480] 10.1111/j.1464-5491.2006.01914.x </p> <p> <b>Ristic, 2006 : </b> Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher ENateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. <i>Diabetes Obes Metab 2007;9:506-11</i> [PMID 17587393] 10.1111/j.1463-1326.2006.00632.x </p> <p> <b>Marre, 2002 : </b> Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard CNateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. <i>Diabetes Obes Metab 2002;4:177-86</i> [PMID 12047396] </p> <p> <b>Moses, 1999 : </b> Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins HEffect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. <i>Diabetes Care 1999;22:119-24</i> [PMID 10333912] </p> <p> <b>Moses, 1999 : </b> Moses RRepaglinide in combination therapy with metformin in Type 2 diabetes. <i>Exp Clin Endocrinol Diabetes 1999;107 Suppl 4:S136-9</i> [PMID 10522839] 10.1055/s-0029-1212169 </p> <p> <b>Khanolkar, 2008 : </b> Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LMRosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation. <i>Atherosclerosis 2008;197:718-24</i> [PMID 17765245] 10.1016/j.atherosclerosis.2007.07.020 </p> <p> <b>scott, 2008 : </b> Scott R, Loeys T, Davies MJ, Engel SSEfficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. <i>Diabetes Obes Metab 2008;10:959-69</i> [PMID 18201203] 10.1111/j.1463-1326.2007.00839.x </p> <p> <b>Garber, 2006 : </b> Garber A, Klein E, Bruce S, Sankoh S, Mohideen PMetformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. <i>Diabetes Obes Metab 2006;8:156-63</i> [PMID 16448519] 10.1111/j.1463-1326.2005.00570.x </p> <p> <b>Matthews, 2005 : </b> Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner GLong-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. <i>Diabetes Metab Res Rev 2005;21:167-74</i> [PMID 15386821] 10.1002/dmrr.478 </p> <p> <b>Gomez-Perez, 2002 : </b> Gómez-Perez FJ, Fanghänel-Salmón G, Antonio Barbosa J, Montes-Villarreal J, Berry RA, Warsi G, Gould EMEfficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. <i>Diabetes Metab Res Rev 2002;18:127-34</i> [PMID 11994904] 10.1002/dmrr.264 </p> <p> <b>Fonseca, 2000 : </b> Fonseca V, Rosenstock J, Patwardhan R, Salzman AEffect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. <i>JAMA 2000;283:1695-702</i> [PMID 10755495] </p> <p> <b>Hamann, 2008 : </b> Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart MComparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. <i>Exp Clin Endocrinol Diabetes 2008;116:6-13</i> [PMID 18095238] 10.1055/s-2007-984441 </p> <p> <b>Bolli, 2008 : </b> Bolli G, Dotta F, Rochotte E, Cohen SEEfficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. <i>Diabetes Obes Metab 2008;10:82-90</i> [PMID 18034842] 10.1111/j.1463-1326.2007.00820.x </p> <p> <b>Bolli, 2008 : </b> Bolli G, Dotta F, Colin L, Minic B, Goodman MComparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. <i>Diabetes Obes Metab 2009;11:589-95</i> [PMID 19515179] 10.1111/j.1463-1326.2008.01023.x </p> <p> <b>Nauck (Sulf vs pbo), 2009 : </b> Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DREfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. <i>Diabetes Care 2009;32:84-90</i> [PMID 18931095] 10.2337/dc08-1355 </p> <p> <b>Nauck (vs GLP-1 analog), 2009 : </b> Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DREfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. <i>Diabetes Care 2009;32:84-90</i> [PMID 18931095] 10.2337/dc08-1355 </p> <p> <b>Khanolkar, 2008 : </b> Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LMRosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation. <i>Atherosclerosis 2008;197:718-24</i> [PMID 17765245] 10.1016/j.atherosclerosis.2007.07.020 </p> <p> <b>Hamann, 2008 : </b> Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart MComparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. <i>Exp Clin Endocrinol Diabetes 2008;116:6-13</i> [PMID 18095238] 10.1055/s-2007-984441 </p> <p> <b>Nauck, 2007 : </b> Nauck MA, Meininger G, Sheng D, Terranella L, Stein PPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. <i>Diabetes Obes Metab 2007;9:194-205</i> [PMID 17300595] 10.1111/j.1463-1326.2006.00704.x </p> <p> <b>Garber, 2006 : </b> Garber A, Klein E, Bruce S, Sankoh S, Mohideen PMetformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. <i>Diabetes Obes Metab 2006;8:156-63</i> [PMID 16448519] 10.1111/j.1463-1326.2005.00570.x </p> <p> <b>Ristic, 2006 : </b> Ristic S, Collober-Maugeais C, Pecher E, Cressier FComparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. <i>Diabet Med 2006;23:757-62</i> [PMID 16842480] 10.1111/j.1464-5491.2006.01914.x </p> <p> <b>Ristic, 2006 : </b> Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher ENateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. <i>Diabetes Obes Metab 2007;9:506-11</i> [PMID 17587393] 10.1111/j.1463-1326.2006.00632.x </p> <p> <b>Feinglos, 2005 : </b> Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, Chaiken R, Kourides IEffect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. <i>Diabetes Res Clin Pract 2005;68:167-75</i> [PMID 15860246] 10.1016/j.diabres.2004.09.002 </p> <p> <b>Charpentier, 2001 : </b> Charpentier G, Fleury F, Kabir M, Vaur L, Halimi SImproved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. <i>Diabet Med 2001;18:828-34</i> [PMID 11678974] </p> <p> <b>Matthews, 2005 : </b> Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner GLong-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. <i>Diabetes Metab Res Rev 2005;21:167-74</i> [PMID 15386821] 10.1002/dmrr.478 </p> <p> <b>Li, 2009 : </b> Li C, Xia J, Zhang G, Wang S, Wang LNateglinide versus repaglinide for type 2 diabetes mellitus in China. <i>Acta Diabetol 2009 Dec;46:325-33</i> [PMID 19183841] </p> <p> <b>Li, 2007 : </b> Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, Ni Z, Yu H, Liang J, Luo R, Li Y, Huang LImprovement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. <i>Diabetes Obes Metab 2007 Jul;9:558-65</i> [PMID 17587398] </p> <p> <b>Lund, 2007 : </b> Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag ATargeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. <i>Diabetes Obes Metab 2007 May;9:394-407</i> [PMID 17391168] </p> <p> <b>Pratley, 2010 : </b> Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies MLiraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. <i>Lancet 2010 Apr 24;375:1447-1456</i> [PMID 20417856] 10.1016/S0140-6736(10)60307-8 </p> <p> <b>Bailey, 2010 : </b> Bailey CJ, Gross JL, Pieters A, Bastien A, List JFEffect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. <i>Lancet 2010 Jun 26;375:2223-2233</i> [PMID 20609968] 10.1016/S0140-6736(10)60407-2 </p> <p> <b>DURATION-3 (Diamant), 2010 : </b> Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann MOnce weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. <i>Lancet 2010 Jun 26;375:2234-2243</i> [PMID 20609969] 10.1016/S0140-6736(10)60406-0 </p> <p> <b>DURATION-2 (Bergenstal) (vs sitagliptin), 2010 : </b> Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LEEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. <i>Lancet 2010 Jun 25;:</i> [PMID 20580422] 10.1016/S0140-6736(10)60590-9 </p> <p> <b>DURATION-2 (Bergenstal) (vs pioglitazone), 2010 : </b> Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor KDURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. <i>Diabet Med 2011 Mar 22;:</i> [PMID 21434995] 10.1111/j.1464-5491.2011.03301.x </p> <p> <b>LEAD-6, 2009 : </b> Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde LLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). <i>Lancet 2009 Jul 4;374:39-47</i> [PMID 19515413] 10.1016/S0140-6736(09)60659-0 </p> <p> <b>LEAD-6, 2009 : </b> Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock JSwitching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. <i>Diabetes Care 2010;33:1300-3</i> [PMID 20332351] 10.2337/dc09-2260 </p> <p> <b>Hallsten, 2002 : </b> Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila PRosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. <i>Diabetes 2002;51:3479-85</i> [PMID 12453903] </p> <p> <b>Pavo, 2003 : </b> Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MHEffect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. <i>J Clin Endocrinol Metab 2003;88:1637-45</i> [PMID 12679450] </p> <p> <b>Hanefeld, 2004 : </b> Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BHOne-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. <i>Diabetes Care 2004;27:141-7</i> [PMID 14693980] </p> <p> <b>Lawrence, 2004 : </b> Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPFavorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. <i>Diabetes Care 2004;27:41-6</i> [PMID 14693964] </p> <p> <b>Ramachandran, 2004 : </b> Ramachandran A, Snehalatha C, Salini J, Vijay VUse of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. <i>J Assoc Physicians India 2004;52:459-63</i> [PMID 15645955] </p> <p> <b>Schernthaner, 2004 : </b> Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti PEfficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. <i>J Clin Endocrinol Metab 2004;89:6068-76</i> [PMID 15579760] 10.1210/jc.2003-030861 </p> <p> <b>Yamanouchi, 2005 : </b> Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki TComparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. <i>Diabet Med 2005;22:980-5</i> [PMID 16026361] 10.1111/j.1464-5491.2005.01656.x </p> <p> <b>Bailey, 2005 : </b> Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MWRosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. <i>Clin Ther 2005;27:1548-61</i> [PMID 16330291] 10.1016/j.clinthera.2005.10.012 </p> <p> <b>EMPIRE (Weissman), 2005 : </b> Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJEffects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. <i>Curr Med Res Opin 2005;21:2029-35</i> [PMID 16368054] 10.1185/030079905X74844 </p> <p> <b>Rosenstock, 1993 : </b> Rosenstock J, Corrao PJ, Goldberg RB, Kilo CDiabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. <i>Clin Ther 1993;15:1031-40</i> [PMID 8111800] </p> <p> <b>Birkeland, 1994 : </b> Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler SLong-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. <i>Diabetes Care 1994;17:45-9</i> [PMID 8112188] </p> <p> <b>Draeger, 1996 : </b> Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Rosskamp RLong-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. <i>Horm Metab Res 1996;28:419-25</i> [PMID 8911976] 10.1055/s-2007-979830 </p> <p> <b>Dills, 1996 : </b> Dills DG, Schneider JClinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. <i>Horm Metab Res 1996;28:426-9</i> [PMID 8911977] 10.1055/s-2007-979831 </p> <p> <b>Inukai, 2005 : </b> Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, Awata T, Katayama SEfficacy of glimepiride in Japanese type 2 diabetic subjects. <i>Diabetes Res Clin Pract 2005;68:250-7</i> [PMID 15936468] 10.1016/j.diabres.2004.10.002 </p> <p> <b>Horton, 2000 : </b> Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen SNateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. <i>Diabetes Care 2000;23:1660-5</i> [PMID 11092289] </p> <p> <b>Hanefeld, 1990 : </b> Hanefeld M, Bouter KP, Dickinson S, Guitard CRapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. <i>Diabetes Care 2000;23:202-7</i> [PMID 10868832] </p> <p> <b>Saloranta, 2002 : </b> Saloranta C, Hershon K, Ball M, Dickinson S, Holmes DEfficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. <i>J Clin Endocrinol Metab 2002;87:4171-6</i> [PMID 12213867] </p> <p> <b>Mari, 2005 : </b> Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini EBeta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. <i>Diabetes Care 2005;28:1132-8</i> [PMID 15855578] </p> <p> <b>Goldberg, 1998 : </b> Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RGA randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. <i>Diabetes Care 1998;21:1897-903</i> [PMID 9802740] </p> <p> <b>Jovanovic, 2000 : </b> Jovanovic L, Dailey G 3rd, Huang WC, Strange P, Goldstein BJRepaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. <i>J Clin Pharmacol 2000;40:49-57</i> [PMID 10631622] </p> <p> <b>Bech, 2003 : </b> Bech P, Moses R, Gomis RThe effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study. <i>Qual Life Res 2003;12:413-25</i> [PMID 12797714] </p> <p> <b>Moses, 2001 : </b> Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov IFlexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. <i>Diabetes Care 2001;24:11-5</i> [PMID 11194214] </p> <p> <b>Garber, 2002 : </b> Garber AJ, Larsen J, Schneider SH, Piper BA, Henry DSimultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. <i>Diabetes Obes Metab 2002;4:201-8</i> [PMID 12047399] </p> <p> <b>Birkeland, 1994 : </b> Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler SLong-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. <i>Diabetes Care 1994;17:45-9</i> [PMID 8112188] </p> <p> <b>Simonson, 1997 : </b> Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CTEfficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. <i>Diabetes Care 1997;20:597-606</i> [PMID 9096986] </p> <p> <b>Vray, 1995 : </b> Vray M, Attali JRRandomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Chinese-French Scientific Committee for the Study of Diabetes. <i>Diabete Metab 1995;21:433-9</i> [PMID 8593925] </p> <p> <b>Testa, 1998 : </b> Testa MA, Simonson DCHealth economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. <i>JAMA 1998;280:1490-6</i> [PMID 9809729] </p> <p> <b>Cefalu, 1998 : </b> Cefalu WT, Bell-Farrow A, Wang ZQ, McBrideD, Dalgleish D, Terry JG.Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM <i>Drug Dev. Res. 1998; 44(1):1-7. </i> [PMID ] </p> <p> <b>Goldberg, 1996 : </b> Goldberg RB, Holvey SM, Schneider JA dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. <i>Diabetes Care 1996;19:849-56</i> [PMID 8842603] </p> <p> <b>Schade, 1998 : </b> Schade DS, Jovanovic L, Schneider JA placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. <i>J Clin Pharmacol 1998;38:636-41</i> [PMID 9702849] </p> <p> <b>Rosenstock, 1996 : </b> Rosenstock J, Samols E, Muchmore DB, Schneider JGlimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. <i>Diabetes Care 1996;19:1194-9</i> [PMID 8908379] </p> <p> <b>Luis Bautista, 2003 : </b> Luis Bautista J, Bugos C, Dirnberger G, Atherton TEfficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. <i>Clin Ther 2003;25:194-209</i> [PMID 12637120] </p> <p> <b>Garber, 2002 : </b> Garber AJ, Larsen J, Schneider SH, Piper BA, Henry DSimultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. <i>Diabetes Obes Metab 2002;4:201-8</i> [PMID 12047399] </p> <p> <b>Charpentier, 2001 : </b> Charpentier G, Fleury F, Kabir M, Vaur L, Halimi SImproved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. <i>Diabet Med 2001;18:828-34</i> [PMID 11678974] </p> <p> <b>Willms, 1999 : </b> Willms B, Ruge DComparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. <i>Diabet Med 1999;16:755-61</i> [PMID 10510952] </p> <p> <b>Manzella, 2004 : </b> Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso GBlood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. <i>Am J Hypertens 2004;17:223-7</i> [PMID 15001195] 10.1016/j.amjhyper.2003.11.006 </p> <p> <b>Del Prato, 2003 : </b> Del Prato S, Erkelens DW, Leutenegger MSix-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. <i>Acta Diabetol 2003;40:20-7</i> [PMID 12682825] 10.1007/s005920300004 </p> <p> <b>Grant, 1996 : </b> Grant PJThe effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. <i>Diabetes Care 1996;19:64-6</i> [PMID 8720537] </p> <p> <b>Schneider, 1991 : </b> Schneider JEffects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. <i>Diabete Metab 1991;17:185-90</i> [PMID 1936474] </p> <p> <b>Garber, 1997 : </b> Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JLEfficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. <i>Am J Med 1997;103:491-7</i> [PMID 9428832] </p> <p> <b>Lee, 1998 : </b> Lee A, Morley JEMetformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. <i>Obes Res 1998;6:47-53</i> [PMID 9526970] </p> <p> <b>Dornan, 1991 : </b> Dornan TL, Heller SR, Peck GM, Tattersall RBDouble-blind evaluation of efficacy and tolerability of metformin in NIDDM. <i>Diabetes Care 1991;14:342-4</i> [PMID 2060439] </p> <p> <b>Hermann, 1991 : </b> Hermann LS, Bitzén PO, Kjellström T, Lindgärde F, Scherstén BComparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. <i>Diabete Metab 1991;17:201-8</i> [PMID 1936477] </p> <p> <b>Hermann, 1994 : </b> Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander ATherapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. <i>Diabetes Care 1994;17:1100-9</i> [PMID 7821128] </p> <p> <b>DeFronzo, 1995 : </b> DeFronzo RA, Goodman AMEfficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. <i>N Engl J Med 1995;333:541-9</i> [PMID 7623902] 10.1056/NEJM199508313330902 </p> <p> <b>Erle, 1999 : </b> Erle G, Lovise S, Stocchiero C, Lora L, Coppini A, Marchetti P, Merante DA comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. <i>Acta Diabetol 1999;36:61-5</i> [PMID 10436254] </p> <p> <b>Charpentier, 2001 : </b> Charpentier G, Vaur L, Halimi S, Fleury F, Derobert E, Grimaldi A, Oriol V, Etienne S, Altman JJPredictors of response to glimepiride in patients with type 2 diabetes mellitus. <i>Diabetes Metab 2001;27:563-71</i> [PMID 11694855] </p> <p> <b>Garber, 2002 : </b> Garber AJ, Bruce S, Fiedorek FTDurability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. <i>Clin Ther 2002;24:1401-13</i> [PMID 12380632] </p> <p> <b>Marre (ass), 2002 : </b> Marre M, Howlett H, Lehert P, Allavoine TImproved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. <i>Diabet Med 2002;19:673-80</i> [PMID 12147149] </p> <p> <b>Blonde, 2002 : </b> Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry DGlyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. <i>Diabetes Obes Metab 2002;4:368-75</i> [PMID 12406033] </p> <p> <b>Goldstein, : </b> Goldstein BJ, Pans M, Rubin CJMulticenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. <i>Clin Ther 2003;25:890-903</i> [PMID 12852706] </p> <p> <b>Tosi, 2003 : </b> Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A, Moghetti PCombination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. <i>Metabolism 2003;52:862-7</i> [PMID 12870162] </p> <p> <b>Garber, 2003 : </b> Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JSEfficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. <i>J Clin Endocrinol Metab 2003;88:3598-604</i> [PMID 12915642] </p> <p> <b>Marre (ass) (ass vs glyburide), 2002 : </b> Marre M, Howlett H, Lehert P, Allavoine TImproved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. <i>Diabet Med 2002;19:673-80</i> [PMID 12147149] </p> <p> <b>Blonde (vs metformin), 2002 : </b> Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry DGlyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. <i>Diabetes Obes Metab 2002;4:368-75</i> [PMID 12406033] </p> <p> <b>Garber (vs glyburide), 2003 : </b> Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JSEfficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. <i>J Clin Endocrinol Metab 2003;88:3598-604</i> [PMID 12915642] </p> <p> <b>linagliptin phase 3 (metformin inappropriate), 0 : </b> 1Barnett AH, Harper R, Toorawa R, et al. Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for whom metformin therapy is inappropriate. Poster no. 823-P, <i>46th European Association for the Study of Diabetes Annual Meeting, September 2010, Stockholm, Sweden.</i> [PMID ] </p> <p> <b>Lewin, 2010 : </b> Lewin AJ, Arvay L, Liu D, et al.Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Poster no. 821-P, <i>46th European Association for the Study of Diabetes Annual Meeting, September 2010, Stockholm, Sweden </i> [PMID ] </p> <p> <b>linagliptin phase 3 Owens, 0 : </b> Owens DR, Swallow R, Woerle HJ, et al.Linagliptin improves glycemic control in Type 2 diabetes patients inadequately controlled by metformin and sulfonylurea without weight gain and low risk of hypoglycaemia. Poster no 548-P, <i>70th American Diabetes Association Scientific Sessions, June 2010, Orlando, Florida U.S.A. </i> [PMID ] </p> <p> <b>linagliptin monotherapy, 0 : </b> Del Prato S, Barnett A, Huisman H, et al.Linagliptin monotherapy improves glycaemic control and measures of beta-cell function in Type 2 diabetes. Poster no 695-P, <i>70th American Diabetes Association Scientific Sessions, June 2010, Orlando, Florida, U.S.A </i> [PMID ] </p> <p> <b>Buse, 2011 : </b> Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock JUse of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. <i>Ann Intern Med 2011 Jan 18;154:103-12</i> [PMID 21138825] 10.1059/0003-4819-154-2-201101180-00300 </p> <p> <b>Protocol 311, : </b> Draeger E, Rosskamp R, Lomp H-J, et al.Multicenter clinical trial to study the effects of glimepiride during long-term treatment of type II diabetic patients; double-blind, parallel-group comparison of glimepiride and Euglucon N (micronised glibenclamide). <i>Protocol 311. Hoechst AG.</i> [PMID ] </p> <p> <b>Clark (301), 1997 : </b> Clark Jr CM, Goldberg RB.Glimepiride dosing and efficacy: results of placebo-controlled, dose-regimen, and active-controlled trials <i>Postgrad Med 1997 Jun Special Report: 45-56 </i> [PMID ] </p> <p> <b>Kaneko, 1993 : </b> Kaneko T, Kaku K, Sakamoto N, et al.Study on minimum effective dose of glimepiride (HOE490) for non-insulin dependent diabetes mellitus patients. Multi center double blind trial compared to placebo [in Japanese] <i>Rinsho Iyaku 1993; 9 (4): 827-48 </i> [PMID ] </p> <p> <b>Study 202, : </b> Hoechst-Roussel Pharmaceuticals Inc. USA.A placebo controlled, dose-titration study of HOE490 in patients with noninsulin- dependent diabetes mellitus (NIDDM) <i>Protocol 202.</i> [PMID ] </p> <p> <b>Sonnenberg, 1997 : </b> Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, DeChemey GS, Mullican WS, Stonesifer LDShort-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. <i>Ann Pharmacother 1997;31:671-6</i> [PMID 9184703] </p> <p> <b>Charpentier (301F), : </b> Charpentier G.Comparative double-blind study of the effective dosages of glimepiride and gliclazide in non-insulin-dependent diabetics <i>Protocol 301F. Laboratoires Hoechst, France </i> [PMID ] </p> <p> <b>Riddle, 1994 : </b> Riddle M, Schneider J, Glimepiride CG.Glimepiride (HOE490) combined with insulin for NIDDM secondary failures to sulfonylurea monotherapy: results of a multicenter trial [abstract]. <i>15th Int Diab Fed Congr 1994: 418 </i> [PMID ] </p> <p> <b>Labor, 1990 : </b> Lalor BC, Bhatnagar D, Winocour PH, Ishola M, Arrol S, Brading M, Durrington PNPlacebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. <i>Diabet Med 1990;7:242-5</i> [PMID 2158410] </p> <p> <b>Nagi, 1993 : </b> Nagi DK, Yudkin JSEffects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. <i>Diabetes Care 1993;16:621-9</i> [PMID 8462390] </p> <p> <b>Johnson, 1993 : </b> Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, Taylor RThe impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. <i>Metabolism 1993;42:1217-22</i> [PMID 8412779] </p> <p> <b>Tessari, 1994 : </b> Tessari P, Biolo G, Bruttomesso D, Inchiostro S, Panebianco G, Vedovato M, Fongher C, Tiengo AEffects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes. <i>J Clin Endocrinol Metab 1994;79:1553-60</i> [PMID 7989455] </p> <p> <b>Grant, 1996 : </b> Grant PJThe effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. <i>Diabetes Care 1996;19:64-6</i> [PMID 8720537] </p> <p> <b>Rains, 1988 : </b> Rains SG, Wilson GA, Richmond W, Elkeles RSThe effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. <i>Diabet Med 1988;5:653-8</i> [PMID 2975549] </p> <p> <b>Collier, 1989 : </b> Collier A, Watson HH, Patrick AW, Ludlam CA, Clarke BFEffect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. <i>Diabete Metab 1989;15:420-5</i> [PMID 2534084] </p> <p> <b>Josephkutty, 1990 : </b> Josephkutty S, Potter JMComparison of tolbutamide and metformin in elderly diabetic patients. <i>Diabet Med 1990;7:510-4</i> [PMID 2142054] </p> <p> <b>Hermann, 1991 : </b> Hermann LS, Karlsson JE, Sjöstrand AProspective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. <i>Eur J Clin Pharmacol 1991;41:263-5</i> [PMID 1748145] </p> <p> <b>Noury, 1991 : </b> Noury J, Nandeuil AComparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. <i>Diabete Metab 1991;17:209-12</i> [PMID 1936478] </p> <p> <b>Boyd, 1992 : </b> Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DRInsulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. <i>Diabetes Res 1992;19:69-76</i> [PMID 1286541] </p> <p> <b>Hermann, 1994 : </b> Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander ATherapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. <i>Diabetes Care 1994;17:1100-9</i> [PMID 7821128] </p> <p> <b>Campbell, 1994 : </b> Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IROne year comparative trial of metformin and glipizide in type 2 diabetes mellitus. <i>Diabete Metab 1994;20:394-400</i> [PMID 7843470] </p> <p> <b>Chuang, 1999 : </b> Chuang LM, Tai TY, Juang JH, et al.Effect of a prandial glucose regulator (NovoNorm®) at two doses (0.5mg and 2.0mg) on glycemic control in type 2 diabetes in Taiwan <i>JAMA SE Asia 1999; 51 (1): 22-5 </i> [PMID ] </p> <p> <b>Landgraf, 1999 : </b> Landgraf R, Bilo HJ, Müller PGA comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. <i>Eur J Clin Pharmacol 1999;55:165-71</i> [PMID 10379630] </p> <p> <b>Marbury, 1999 : </b> Marbury T, Huang WC, Strange P, Lebovitz HRepaglinide versus glyburide: a one-year comparison trial. <i>Diabetes Res Clin Pract 1999;43:155-66</i> [PMID 10369424] </p> <p> <b>Wolffenbuttel, 1999 : </b> Wolffenbuttel BH, Landgraf RA 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. <i>Diabetes Care 1999;22:463-7</i> [PMID 10097930] </p> <p> <b>Madsbad, 2001 : </b> Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard AComparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. <i>Diabet Med 2001;18:395-401</i> [PMID 11472451] </p> <p> <b>Raskin, 2000 : </b> Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner RRepaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. <i>Diabetes Care 2000;23:979-83</i> [PMID 10895850] </p> <p> <b>Raskin, 2001 : </b> Raskin P, McGill J, Hale P, et al.Repaglinide/rosiglitazone combination therapy of type 2 diabetes <i>Diabetes 2001; 50 Suppl. 2: A128 </i> [PMID ] </p> <p> <b>Raskin, 2001 : </b> Jovanovic L, Jain R, Greco S, et al.Repaglinide/pioglitazone combination therapy of type 2 diabetes <i>Diabetes 2001; 50 Suppl. 2: A439</i> [PMID ] </p> <p> <b>Landin-Olsson, 1999 : </b> Landin-OlssonM, Brogard JMM, Eriksson J, et al.The efficacy of repaglinide administered in combination with bedtime NPH-insulin in patients with type 2 diabetes. A randomized, semi-blinded, parallel-group, multi-centre trial [abstract] <i>Diabetes 1999 May; 48 Suppl. 1: A117 </i> [PMID ] </p> <p> <b>Goldberg, 1998 : </b> Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RGA randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. <i>Diabetes Care 1998;21:1897-903</i> [PMID 9802740] </p> <p> <b>Jovanovic, 2000 : </b> Jovanovic L, Dailey G 3rd, Huang WC, Strange P, Goldstein BJRepaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. <i>J Clin Pharmacol 2000;40:49-57</i> [PMID 10631622] </p> <p> <b>Gao, 0 : </b> Gao X, , Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. <i>J Int Med Res ;37:812-21.</i> [PMID 19589264] </p> <p> <b>Kaku, 2009 : </b> Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y, Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. <i>Endocr J 2009;56:657-64.</i> [PMID 19352048] </p> <p> <b>Kumashiro, 2007 : </b> Kumashiro N, Yoshihara T, Kanazawa Y, Shimizu T, Watada H, Tanaka Y, Fujitani Y, Kawamori R, Hirose T, Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. <i>Endocr J 2007;54:163-6.</i> [PMID 17185877] </p> <p> <b>Filozof, 2009 : </b> Filozof C, Gautier JFA comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. <i>Diabet Med 2010 Mar;27:318-26</i> [PMID 20536495] 10.1111/j.1464-5491.2010.02938.x </p> <p> <b>COSMIC, 2009 : </b> Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BVComparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. <i>Diabetes Care 2005;28:539-43</i> [PMID 15735184] </p> <p> <b>Lead-3 (Bode), 2010 : </b> Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A, , Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. <i>Diabetes Obes Metab 2010;12:604-12.</i> [PMID 20590735] 10.1111/j.1463-1326.2010.01196.x </p> <p> <b>Hermansen, 2010 : </b> Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D, Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. <i>Prim Care Diabetes 2010;4:113-7.</i> [PMID 20444662] 10.1016/j.pcd.2010.04.001 </p> <p> <b>LEAD-6 ext (Buse), 2010 : </b> Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J, , Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. <i>Diabetes Care 2010;33:1300-3.</i> [PMID 20332351] 10.2337/dc09-2260 </p> <p> <b>Seino, 2010 : </b> Seino Y, Rasmussen MF, Nishida T, Kaku K, Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. <i>Curr Med Res Opin 2010;26:1013-22.</i> [PMID 20199137] 10.1185/03007991003672551 </p> <p> <b>Astrup, 2009 : </b> Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME, , Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. <i>Lancet 2009;374:1606-16.</i> [PMID 19853906] 10.1016/S0140-6736(09)61375-1 </p> <p> <b>Chatterjee, 2009 : </b> Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS, Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. <i>J Clin Pharmacol 2009;49:1353-62.</i> [PMID 19737980] 10.1177/0091270009339189 </p> <p> <b>Nauck, 2009 : </b> Nauck M, Marre M, Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. <i>Postgrad Med 2009;121:5-15.</i> [PMID 19491535] 10.3810/pgm.2009.05.1997 </p> <p> <b>Irie, 2008 : </b> Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S, Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. <i>Int J Clin Pharmacol Ther 2008;46:273-9.</i> [PMID 18541123] </p> <p> <b>Vilsbøll, 2007 : </b> Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S, Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. <i>Diabet Med 2008;25:1129-31.</i> [PMID 19183322] 10.1111/j.1464-5491.2008.02484.x </p> <p> <b>Vilsbøll, 2007 : </b> Horowitz M, Vilsbøll T, Zdravkovic M, Hammer M, Madsbad S, Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. <i>Diabetes Obes Metab 2008;10:593-6.</i> [PMID 18435773] 10.1111/j.1463-1326.2008.00861.x </p> <p> <b>Vilsbøll, 2007 : </b> Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S, Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. <i>Diabetes Care 2007;30:1608-10.</i> [PMID 17372153] 10.2337/dc06-2593 </p> <p> <b>Nauck (LI+MET vs MET), 2006 : </b> Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J, , Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. <i>Exp Clin Endocrinol Diabetes 2006;114:417-23.</i> [PMID 17039422] 10.1055/s-2006-924230 </p> <p> <b>Harder, 2004 : </b> Harder H, Nielsen L, Tu DT, Astrup A, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. <i>Diabetes Care 2004;27:1915-21.</i> [PMID 15277417] </p> <p> <b>Degn, 2004 : </b> Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O, Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. <i>Diabetes Care 2007;30:2032-3.</i> [PMID 17468345] 10.2337/dc07-0310 </p> <p> <b>Degn, 2004 : </b> Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O, One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. <i>Diabetes 2004;53:1187-94.</i> [PMID 15111485] </p> <p> <b>Nauck (LI vs MET), 2006 : </b> Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J, , Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. <i>Exp Clin Endocrinol Diabetes 2006;114:417-23.</i> [PMID 17039422] 10.1055/s-2006-924230 </p> <p> <b>LEAD-2 (vs MET), 2009 : </b> Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ, , Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. <i>Diabetes Obes Metab 2009;11:1163-72.</i> [PMID 19930006] 10.1111/j.1463-1326.2009.01158.x </p> <p> <b>LEAD-2 (vs MET), 2009 : </b> Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DREfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. <i>Diabetes Care 2009 Jan;32:84-90</i> [PMID 18931095] </p> <p> <b>LEAD-2 (vs MET), 2009 : </b> Nauck M, Marre MAdding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. <i>Postgrad Med 2009 May;121:5-15</i> [PMID 19491535] </p> <p> <b>LEAD-2 (vs MET), 2009 : </b> Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde LLong-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. <i>Cardiovasc Diabetol 2009 Feb 26;8:12</i> [PMID 19245711] </p> <p> <b>NN2211-1571 (Vilsbøll 2007), 0 : </b> Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad SLiraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. <i>Diabetes Care 2007 Jun;30:1608-10</i> [PMID 17372153] </p> <p> <b>NN2211-1499 DOUBLONS avec NAUCK 2006, : </b> Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht JFive weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. <i>Exp Clin Endocrinol Diabetes 2006;114:417-23</i> [PMID 17039422] 10.1055/s-2006-924230 </p> <p> <b>Ratner, 2010 : </b> Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R, Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. <i>Diabet Med 2010;27:556-62.</i> [PMID 20536952] 10.1111/j.1464-5491.2010.02990.x </p> <p> <b>Nauck, 2009 : </b> Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R, Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. <i>Diabetes Care 2009;32:1237-43.</i> [PMID 19366970] 10.2337/dc08-1961 </p> <p> <b>Ratner DRI6012, 2010 : </b> Ratner RE, Rosenstock J, Boka GDose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. <i>Diabet Med 2010;27:1024-32</i> [PMID 20722676] 10.1111/j.1464-5491.2010.03020.x </p> <p> <b>Seino, 2009 : </b> Seino Y, Nakajima H, Miyahara H, Kurita T, Bush MA, Yang F, Stewart MW, Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. <i>Curr Med Res Opin 2009;25:3049-57.</i> [PMID 19863477] 10.1185/03007990903372999 </p> <p> <b>Rosenstock, 2009 : </b> Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, , Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. <i>Diabetes Care 2009;32:1880-6.</i> [PMID 19592625] 10.2337/dc09-0366 </p> <p> <b>Bush, 2009 : </b> Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Gutierrez M, Stewart MW, Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. <i>Diabetes Obes Metab 2009;11:498-505.</i> [PMID 19187286] 10.1111/j.1463-1326.2008.00992.x </p> <p> <b>Matthews, 2008 : </b> Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Bush MA, , Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. <i>J Clin Endocrinol Metab 2008;93:4810-7.</i> [PMID 18812476] 10.1210/jc.2008-1518 </p> <p> <b>NCT00111540, : </b> Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle MEMetabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. <i>Clin Ther 2007;29:139-53</i> [PMID 17379054] 10.1016/j.clinthera.2007.01.015 </p> <p> <b>NCT00111540, : </b> Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DGExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Curr Med Res Opin 2008;24:275-86</i> [PMID 18053320] 10.1185/030079908X253870 </p> <p> <b>DeFronzo, 2008 : </b> DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell LEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. <i>Curr Med Res Opin 2008;24:2943-52</i> [PMID 18786299] 10.1185/03007990802418851 </p> <p> <b>8372 (GWAQ), 2008 : </b> Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, de la Peña A, Teng CH, Mace K, Fineman M, Shigeta H, Sakata Y, Irie SPharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. <i>J Clin Pharmacol 2008;48:1389-99</i> [PMID 19047364] 10.1177/0091270008323750 </p> <p> <b>Davis (8070) DOUBLONS, : </b> Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RGExploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. <i>Diabetes Care 2007;30:2767-72</i> [PMID 17595353] 10.2337/dc06-2532 </p> <p> <b>Fineman, 2003 : </b> Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron ADEffect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. <i>Diabetes Care 2003;26:2370-7</i> [PMID 12882864] </p> <p> <b>Kolterman A, 2003 : </b> Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron ADSynthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. <i>J Clin Endocrinol Metab 2003;88:3082-9</i> [PMID 12843147] </p> <p> <b>Calara, 2005 : </b> Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman MA randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). <i>Clin Ther 2005;27:210-5</i> [PMID 15811484] 10.1016/j.clinthera.2005.02.008 </p> <p> <b>Blase, 2005 : </b> Blase E, Taylor K, Gao HY, Wintle M, Fineman MPharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. <i>J Clin Pharmacol 2005;45:570-7</i> [PMID 15831781] 10.1177/0091270004274432 </p> <p> <b>Fehse, 2005 : </b> Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MAExenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. <i>J Clin Endocrinol Metab 2005;90:5991-7</i> [PMID 16144950] 10.1210/jc.2005-1093 </p> <p> <b>Poon, 2005 : </b> Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim DExenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. <i>Diabetes Technol Ther 2005;7:467-77</i> [PMID 15929678] 10.1089/dia.2005.7.467 </p> <p> <b>Degn, 2004 : </b> Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz OEffect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. <i>Diabetes 2004;53:2397-403</i> [PMID 15331551] </p> <p> <b>Zinman, 2007 : </b> Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RGThe effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. <i>Ann Intern Med 2007;146:477-85</i> [PMID 17404349] </p> <p> <b>Schwartz, 2008 : </b> Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JHEffect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. <i>Clin Ther 2008;30:858-67</i> [PMID 18555933] 10.1016/j.clinthera.2008.05.004 </p> <p> <b>9607, 2009 : </b> Gao Y, Yoon KH, Chuang LM, Mohan V, Ning G, Shah S, Jang HC, Wu TJ, Johns D, Northrup J, Brodows REfficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. <i>Diabetes Res Clin Pract 2009;83:69-76</i> [PMID 19019476] 10.1016/j.diabres.2008.09.037 </p> <p> <b>Cervera, 2008 : </b> Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo EMechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. <i>Am J Physiol Endocrinol Metab 2008;294:E846-52</i> [PMID 18334612] 10.1152/ajpendo.00030.2008 </p> <p> <b>Kolterman B, 2003 : </b> Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron ADSynthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. <i>J Clin Endocrinol Metab 2003;88:3082-9</i> [PMID 12843147] </p>